药明巨诺
JW Therapeutics

JW (Cayman) Therapeutics Co. Ltd
藥明巨諾(開曼)有限公司*
(Incorporated in the Cayman Islands with limited liability)
Stock Code: 2126

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2024

* For identification purpose only

Contents

MESSAGE FROM THE CHAIRMAN AND CHIEF EXECUTIVE OFFICER

Dear Readers,

On behalf of the Board of Directors, I am pleased to present JW Therapeutics' 2024 Environmental, Social, and Governance (ESG) Report.

In 2024, JW Therapeutics demonstrated outstanding performance in a competitive market, achieving continuous breakthroughs. In this year, we deepened our focus on core technologies of CAR-T therapies, maintained our commitment to cutting-edge and innovative products, strengthened recognition within the medical community, and brought hope to more patients and their families in China. As we advanced R&D and clinical research, we upheld robust corporate governance and responsibility, embedding ESG principles into corporate operations to collaboratively build an inclusive, sustainable, and resilient future with all stakeholders.

Solid Corporate Governance

We aim to enhance governance efficiency, strengthen risk management capabilities, and solidify ESG integration. By establishing a scientific and robust governance framework, we prioritize diversity principles in appointing Board members and clarifying director responsibilities to guide corporate governance with a more comprehensive and broader perspective. In the year of 2024, the Board and shareholders worked collaboratively to support critical business milestones, ensuring maximized value for all stakeholders. We continuously conducted our operations in an ethical and compliant manner, reinforced compliance awareness and business ethics across the Board and leadership, and implemented a holistic internal control and risk management structure. In addition, through data leakage prevention management and security alerting systems, we implement comprehensive data risk management, as well as annual assessments and compliant disclosures, safeguarding the stability of operations.

Hopes for Cure

Our mission is to deliver breakthrough, high-quality cell immunotherapy products to patients in China and globally, thereby fostering the positive development of the industry. We have promoted the expansion of our diverse product pipelines, strictly adhered to industry standards, and applied standardized R&D processes with rigorous intellectual property and data privacy policies. Upholding an innovative mindset, we formulate precise strategies according to industrial demands and market outlook and continue developing innovative products while ensuring product quality, to deliver revolutionary and emerging treatments to patients. We consistently prioritize product quality assurance, actively assume product responsibility, formulate our quality policy, establish a comprehensive quality monitoring system, foster a quality culture, and implement quality management across the whole chain from production to medical treatment, solidifying our leadership in the field of hematologic malignancies.

Patient First

Guided by our value of "Patients First", we have implemented a patient-centric "6P Strategy", involving key stakeholders across the CAR-T therapy process. By managing all the treatment phases of the entire treatment process, we assist patients with high-quality care and holistic support. We have specific teams to oversee strict process management and quality control to optimize treatment outcomes and experiences for patients. Furthermore, we are committed to enhancing the accessibility and affordability of the products, providing more support to improve patients' health and welfare. Collaborating with healthcare professionals, business partners, and regulatory agencies, strive to promote standardized and high-quality development of the industry. In addition, we adhere to pharmacovigilance and legal requirements during commercialization, ensuring patients' medical safety.

Eco-friendly Development

Aligned with the national strategy of "carbon peaking and carbon neutrality", JW Therapeutics actively embedded sustainable practices across operations. Under the supervision of the Board of Directors, the EHS Committee has been established to oversee the conduction of climate-related risk analysis and risk management procedures. Complying with environmental laws and regulations, we take various measures in operations and manufacturing, monitoring product environmental data, to conserve natural resources and reduce the impacts on the environment. Through continuous monitoring and assessment of key performance indicators, such as energy consumption, GHG emissions, water consumption, and waste disposal, we closely track our environmental performance to ensure satisfactory progress in achieving environmental targets.

Mr. Min Liu
Chairman and CEO

> *"Based on the Company's core values of putting patients first, JW Therapeutics actively explores solutions to meet the challenges of commercialization of innovative products, and strives to improve the accessibility and affordability of products, so that cell immunotherapy can benefit more patients."*

People Oriented

We strictly adhere to labor regulations and effectively guarantee the benefits of employees. We advocate for a people-oriented culture workplace, offering incentives to widely attract top talent. We consistently pay attention to employees' benefits, guarantee and occupational health and safety, foster a diverse, equitable, and inclusive culture, and cultivate an open and transparent working environment by promoting two-way communication. Through scientific performance evaluation systems, as well as a training mechanism with "Excellence in Onboarding", "Leadership Effectiveness" and "Organizational Effectiveness" as the three main pillars, we provide multi-level training and career development opportunities to enhance employees' motivation and optimize the organizational structure to improve the efficiency of corporate operation. We also continuously strengthen our health and safety risk control mechanisms to provide solid protection for the physical and mental well-being of our employees.

Responsible Citizen

Beyond business growth, we also attach great importance to sustainable supply chain, promote healthy development of the industry and engage in public welfare initiatives. We apply lifecycle management strategy, regular performance evaluations and training to suppliers, to enhance the stability and sustainability of our supply chain. Besides, we actively engage in a variety of industrial and academic conferences and bring warmth and hope to patients through our participation in philanthropic initiatives.

I sincerely invite you to read our report to explore our 2024 ESG performance and progress in detail. Moving forward, JW Therapeutics will continue collaborating with our stakeholders to create mutually beneficial outcomes and deliver innovative and high-quality therapies to global patients, advancing the healthy development of the cell immunotherapy sector in China and worldwide. We are looking forward to working with you to build a better future for medical health.

ABOUT THIS REPORT

The report is the fifth Environmental, Social, and Governance ("ESG") Report ("ESG Report" or the "Report") issued by JW (Cayman) Therapeutics Co. Ltd (the "Company"), its subsidiaries and consolidated affiliated entity ("JW Therapeutics", the "Group" or "we"). This report is to explain the Company's strategies, policies, measures and achievements in sustainability to all stakeholders objectively and fairly, and focus on the disclosure of information on the Company's performance in ESG.

Reporting Period

The period of the Report covers the information and data of the Company from January 1, 2024 to December 31, 2024 (the "Reporting Period"), with some content dating back to previous years or extending to future years, to ensure the completeness and continuity of reporting.

Reporting Boundary

The boundary of the Report covers the core business of the Group, including our manufacturing sites, R&D centers, and offices in Shanghai and Suzhou.

Reporting Standards and Principles

The Report has been prepared in accordance with the *Environmental, Social and Governance Reporting Code* ("the *ESG Reporting Code*") as set out in Appendix C2 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("HKEX"), and with reference to the guidelines of the Task Force on Climate-related Financial Disclosures ("TCFD") and the United Nations Sustainable Development Goals ("SDGs").

The Report has been prepared in accordance with the following reporting principles of the ESG Reporting Code:

- **"Materiality"**: Material ESG issues are identified through communication with stakeholders and materiality assessment, and disclosed in the ESG report.
- **"Quantitative"**: Quantitative information such as environmental and social key performance indicators disclosed in the Report has been accompanied by an explanation, claiming its purpose and impacts.
- **"Balance"**: The Report presents the Company's ESG performance in an impartial manner.
- **"Consistency"**: The Report uses statistical methods consistent with previous years, allowing for meaningful comparisons.

Sources of Information and Assurance of Reliability

The data and examples in the report were derived mainly from the Company's statistical reports and relevant documents. The Company undertakes that the Report does not contain any false records or misleading statements and the Company is responsible for the truthfulness, accuracy, and completeness of its contents.

Access and Response

The Report is published in traditional Chinese and English. In case of any ambiguity between the contents, the English version shall prevail. In consideration of environmental protection, we recommend reading the electronic report, which is provided to our shareholders, and can also be found on the Company's official website (https://www.jwtherapeutics.com/).

We attach great importance to the opinions of our stakeholders and welcome the readers to contact us through the following contact information. Your comments are appreciated for our consideration to continuously improve this report and the overall ESG performance.

Contact information

Media Relations and Business Development:
Communications@jwtherapeutics.com
BD@jwtherapeutics.com

Medical Information and Reporting AE:
Medical.Information@jwtherapeutics.com
PV@jwtherapeutics.com

Whistle-blowing Reporting Channel:
compliance@jwtherapeutics.com
IA@jwtherapeutics.com
Address: Building B, 5/F, Wison Center 666 Haike Road, Pudong New Area, Shanghai, PRC

Confirmation and Approval

The Report was confirmed by management and approved by the board (the "Board") of directors (the "Directors").

ABOUT JW THERAPEUTICS

JW Therapeutics (HKEX Stock code: 2126) is an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products. Founded in 2016, JW Therapeutics has built an internationally leading integrated platform for comprehensive product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors, and autoimmune diseases. JW Therapeutics is committed to bringing breakthrough and quality cell immunotherapy products and the hope of a cure to patients in China and beyond, and to leading the healthy and standardized development of China's cell immunotherapy industry.

We are an early entrant into the field of cell-based immunotherapy in China. Cell-based immunotherapies, including CAR-T treatments, are an innovative treatment method that uses human immune cells to fight cancer, representing a paradigm shift in cancer treatment. Our lead product, Carteyva®, is an autologous anti-CD19 CAR-T cell immunotherapy product independently developed by us based on a CAR-T cell process platform of Juno (a Bristol Myers Squibb company). Carteyva® has been approved by the National Medical Products Administration ("NMPA") for three indications, including the treatment of adult patients with relapsed or refractory large B-cell lymphoma ("r/r LBCL") after two or more lines of systemic therapy, the treatment of adult patients with relapsed or refractory follicular lymphoma ("r/r FL") in which a relapse occurs within 24 months of second-line or higher systemic treatment, and the treatment of adult patients with relapsed or refractory mantle cell lymphoma ("r/r MCL") after two or more lines of systemic therapy including bruton tyrosine kinase inhibitors ("BTKi").

Sales of CAR-T products in China remained relatively stable in 2024, as compared to 2023. Given the unmet medical needs that can be effectively addressed by CAR-T therapies, the market for CAR-T therapies in China is expected to experience strong growth through 2030, according to Frost & Sullivan. We believe that we are well-positioned to take advantage of this growing market, based on the best-in-class potential of our anti-CD19 CAR-T product profile; our robust and differentiated cell therapy pipeline covering hematological cancers, solid tumors and autoimmune diseases; our fully integrated cell therapy development platform; our leading commercial manufacturing infrastructure and supply chain; and our seasoned management and strong support from the shareholders of the Company. In 2024 we made significant progress on the development of Carteyva® for the treatment of hematological malignancies, progressed development of our products for the treatment of solid tumors, and advanced relma-cel as a potential treatment for SLE, an autoimmune disease widely prevalent in China. Carteyva® is the first CAR-T product approved as a Category 1 biologics product in China, and currently it is the only CAR-T product in China that has been simultaneously included in the National Significant New Drug Development Program and granted priority review and breakthrough therapy designations.

JW Therapeutics is committed to developing innovative cell therapy methods and continuously driving the industry development as a leader in cell immunotherapy, thereby bringing revolutionary new treatments to patients. We will uphold the concept of "quality first" and devote ourselves to serving patients with world-class quality products, bringing hope of life to patients in China and all over the world.

01

OUR VISION

Become an Innovation Leader in Cell Immunotherapy

02

OUR MISSION

Bring Hope to Patients in China
Work Together and Realize the Potential for JW Therapeutics and Its Employees

03

OUR VALUES

- **Quality-Centered**
- **Results-Oriented**
- **Patient First**
- **Integrity, Respect, Inclusion and Collaboration**
- **Innovation-Driven**

OUR COMMITMENT

To our patients

We are committed to continuously promoting R&D innovation, optimizing product processes, and meeting the unmet medical needs with world-class products. We strive to explore a multi-layer medical care system for treatment and improve the patient affordability through innovative payment and insurance methods.

To our employees

We are committed to supporting our employees to fulfill their career development through an advanced employment, compensation and training management system. We are committed to creating a healthy and safe working environment through competitive employee welfare and care solutions.

To our shareholders

We are committed to promoting business expansion by expanding pipeline and market coverage, realizing economies of scale, achieving revenue growth, and helping maximize the interests of shareholders.

To our communities

We are committed to continuously participating in industrial collaboration and driving the industry development, supporting the government and regulators to formulate industry norms and standards, and contributing to the development of China's cellular immunity industry.

To our environment

We are committed to actively fulfilling environmental goals and reducing the environmental impact of production and operations on resource utilization, energy consumption, waste disposal and other areas, thereby contributing to the sustainable development.

RECOGNITION AND AWARDS IN 2024

Awarded the "2024 Advanced Unit in Safety Production Standardization" by Dushu Lake Science and Education Innovation Zone of Suzhou Industrial Park

In January 2025, JW Therapeutics was recognized as the "2024 Advanced Unit in Safety Production Standardization", presented by the Emergency Management Bureau of Dushu Lake Science and Education Innovation Zone of Suzhou Industrial Park.

Award for 2024 ESG Era Pioneer in the CNR Corporate Social Responsibility Case Selection Activity

On December 26, 2024, the Corporate Social Responsibility case selection held by CNR was held in Beijing. JW Therapeutics won the "2024 ESG Era Pioneer Award" for its case "CAR-T Illuminates New Life for Chinese Patients", which further confirmed the corporate value.

Awarded the "Social Responsibility Enterprise" of the 2024 Safety Production Month by Suzhou Industrial Park Safety Production Alliance

On July 4, 2024, Suzhou Industrial Park Safety Production Alliance's "Safety Production Month" work summary meeting, coupled with the second half of the year "Six Key Initiatives" work promotion meeting was held, where JW Therapeutics was recognized as the "Social Responsibility Enterprise".

Second Prize in the Enterprise Group of the "Zhangjiang Town International Safe Community Occupational Health" Awards

On September 23, 2024, the Supervision Institute of Shanghai Pudong New Area Health Commission and the Zhangjiang International Safe Community Promotion Committee announced the "Zhangjiang Town International Safe Community Occupational Health" awards, where JW Therapeutics received the second prize in the enterprise group.

Awarded the "2024 Green Development Enterprise" in the Environmental Performance Evaluation by Pudong New Area, Shanghai

On November 20, 2024, the Pudong New Area Ecological Environment Bureau of Shanghai announced the results of the 2024 environmental performance evaluation. JW Therapeutics was awarded the title of "2024 Green Development Enterprise" for its outstanding environmental performance.

2024 HIGHLIGHTS

CORPORATE GOVERNANCE AND ESG STRATEGY

Completion Percentage of Compliance and Anti-corruption Training by Employees

100%

Percentage of Female Directors of the Board

25%

(As of the Reporting date)

Number of ESG Issues Assessed for Materiality

22

FINANCIAL PERFORMANCE

Revenue

158.2 million RMB

Gross Profit Margin

48.9%

R&D Expenses Proportion

47.9%

Cash and Cash Equivalents

757.4 million RMB

EMPOWERING EMPLOYEE

Female Employee Proportion

59%

Employee Training Coverage

100%

Training Hours per Employee

25

ENVIRONMENTAL SUSTAINABILITY

Comprehensive Energy Consumption Intensity

0.52 MWh/RMB 10,000 revenue

Comparing with 2021 (base year of the environmental targets)

Declined by 84%

GHG Emissions Intensity

0.25 tCO_2e/RMB10,000 revenue

Declined by 86%

Water Consumption Intensity

1.22 m^3/RMB 10,000 revenue

Declined by 77%

Waste Management

100% compliant disposal of hazardous waste

100% recycling rate of cartons

EFFORTS IN PATIENT AFFORDABILITY

Number of Certified Hospitals[1]

140

Number of Commercial Insurance Products that Carteyva® has been listed on

80+

Number of Local Government Complementary Medical Insurance Programs that Carteyva® has been listed on

102

[1] Certified hospitals refer to medical institutions that have received training and certification by the Company for the use of relma-cel.

1 SOLID GOVERNANCE

— Maintaining solid corporate governance and insisting on operation compliance and sustainable development

UN SDGs	Topics	Actions
	• Board Governance and Diversity • ESG Governance • Stakeholder Engagement and Materiality Analysis • Internal Control and Risk Management • Business Ethics • Information Security	• Establish a diversified Board of Directors and clearly define its powers and responsibilities and balance the experience and skills among Board members • Establish the ESG strategy for corporate sustainable development orientation • Actively communicate with stakeholders, respond to their reasonable demands and expectations, and identify and evaluate the significant issues that are most important to JW Therapeutics • Conduct regular risk assessments, strengthen internal audits, and actively adopt improvement to address and prevent risks • Enforce strict adherence to code of conduct for employees and suppliers, and conduct trainings and internal audits on business ethics and anti-corruption • Enhance information security management systems and carry out information security training for all employees

JW Therapeutics' culture is rooted in a strong foundation of integrity and solid corporate governance. We have established and been continuously optimizing the comprehensive governance system, persistently strengthening internal control and risk management while adhering to the highest ethical standards. We are committed to creating a standardized, transparent, and trustworthy corporate environment to ensure our long-term stable development.

1.1 Board Governance and Diversity

The key to achieving scientific and effective corporate governance lies in the construction of a diversified Board and a clear delineation of its powers and responsibilities. JW Therapeutics is dedicated to enhancing the Board structure and adheres to the principle of diversity in selecting board members. By balancing the experience and skills of Board members, we aim to enhance the overall governance effectiveness of the Board, providing strong assurance for the long-term development of the Company.

1.1.1 Board Governance Effectiveness

JW Therapeutics established the Audit Committee, the Nomination Committee, the Remuneration Committee, and the Business Development and Strategy Committee under the Board to continuously enhance its governance capabilities with a sound governance structure.



Structure of the Board of JW Therapeutics

1.1.2 Board Diversity

JW Therapeutics has formulated a *Board Diversity Policy*, the implementation of which is annually reviewed with the assistance of the Nomination Committee. This initiative aims to ensure the diversity of Board members in professional experience, educational backgrounds, knowledge, ages, and genders, to enhance board efficiency and ensure scientific decision-making. Currently, out of 8 Directors, 2 Directors have ESG management experience, and 6 Directors have corporate governance experience.



Board Diversity of JW Therapeutics

1.2 ESG Governance and Strategy

JW Therapeutics incorporates ESG factors into Company's strategy while cultivating the business and thoroughly implementing the concept of sustainable development throughout the business operation. We drive corporate sustainable development through our integrated platform, strengthened in-house R&D capabilities, and strategic alliance with cooperation partners. Additionally, we actively take environmental and social responsibilities to respond to global challenges such as climate change and extreme weather and focus on talent development and social development to continuously create values.

1.2.1 ESG Strategy

Our Board of Directors has the overall responsibility for the Company's ESG integration and the development of our ESG strategy. Our ESG strategy is rooted in our Vision, Mission and Values, focusing on issues of high priority closely related to our business nature and stakeholders' expectations. The nature of our business aligns closely with the core principles of ESG, and we regard the ESG concept as an essential mindset for our team in our operational management.

JW Therapeutics' ESG strategy outlines a clear path for the Company's sustainable development and identifies strategic directions that can generate the greatest positive impact. We integrate ESG principles into our internal policies in the management and practice of key issues such as business ethics and compliance, comprehensive product quality management, climate change and environmental protection, enhancing product accessibility, guaranteeing employee rights and development, and social and community investment. Our ESG strategy guides the conduct and management of various company affairs. This strategy not only reflects our commitment to social responsibility but also provides a solid foundation for maintaining competitiveness in an increasingly complex and globalized business.

JW Therapeutics ESG Strategy

Under the guidance of our ESG strategy, we have developed the *Environmental, Social and Governance Policy* as the core guiding document for JW Therapeutics' ESG issues. The policy defines the structure, roles and responsibilities of ESG management, and covers the Company's management principles and requirements for key ESG issues including environment, health and safety ("EHS"), environmental protection, resource conservation, quality monitoring, human resources management, protection of the rights and interests of patients, suppliers and partners, public relations and social welfare system, etc.

1.2.2 ESG Governance Structure

In order to better promote the Group's ESG strategy, JW Therapeutics has established a comprehensive ESG governance structure, which consists of the Board, the Risk Management Committee and the ESG Working Group. The roles and responsibilities for each hierarchy are clearly defined as below.

JW Therapeutics ESG Governance Structure

1.2.3 Statement of the Board

The Board's ESG Management Responsibilities

The Board assumes overall responsibility and plays a leading role for the Company's ESG strategy and ESG governance. The responsibilities of the Board defined in ESG policy mainly include:

- Authorize the Risk Management Committee to manage ESG-related risks and implement the ESG strategy, with the Board responsible for guidance, oversight, and review
- Responsible for comprehensive oversight of climate-related risk management, reviewing, and discussing the effectiveness of management strategies
- Ensure the appropriate and effective ESG risk management and internal control systems
- Approve the Company's ESG strategies and policies
- Approve the Company's ESG report

ESG Governance Policy and Strategy

- In order to implement the ESG agenda, the Board delegates the Risk Management Committee to manage ESG-related risks and implement the ESG strategy
- The Committee formulates ESG-related objectives and targets, drives the execution, and ensures compliance with the ESG regulations. The output and recommendation from the committee should be endorsed by the Board
- In addition, an ESG Working Group, supported by IA department, together with related department heads, is responsible for ESG-related policy formulation and the execution of the ESG works

Material ESG Issues Analysis and Assessment and Risk Management

- JW Therapeutics conducts regular communications with stakeholder engagements through various channels to evaluate and identify the Company's material ESG-related issues
- For identified ESG risks, we prioritize them based on their significance and develop corresponding action plans according to their priority, taking measures to mitigate risk impacts to ensure the Company's compliance and operational continuity
- Feedback from the risk management process provides us with a basis for optimizing our ESG strategy. To meet the demands of various stakeholders, we take actions to continuously improve the Company's overall ESG performance
- The Board discusses and approves the ESG strategy, material ESG Issues and risk assessment results, and tracks and oversees the progress made against the ESG targets set periodically

1.2.4 Stakeholder Engagement and Materiality Analysis

We attach great importance to stakeholder engagement and are committed to building strong, collaborative and mutually beneficial relationships with both internal and external stakeholders. JW Therapeutics' key stakeholders include the government and regulatory agencies, investors, suppliers, business partners, communities, customers, and employees. During the Reporting Period, we have conducted regular and close communication with our stakeholders through various communication mechanisms to listen to and respond to their reasonable expectations and demands. We incorporate evaluated significant issues into our Company's business strategy and future planning, and work with stakeholders to pursue win-win results and maximize comprehensive value.

The communication mechanisms with our key stakeholders are as follows:

Key Stakeholders	Issues of Concern	Main communication mechanisms
Government and Regulatory Agencies	• Corporate Governance • Information Security and Privacy Protection • Intellectual Property ("IP") Protection • Public Welfare and Charity • Code of Business Conduct and Anti-Corruption • Anti-unfair competition behavior • Climate Change Response	• Questionnaires • Regular meetings and conferences • Feedback and suggestions on policy
Investors	• Product Research and Innovation • Product Accessibility • IP Protection	• Company official website • Announcement on the HKEX platform • Annual General Meeting (AGM)/ Extraordinary General Meeting (EGM) • Questionnaire • Email and telephone communication • Face-to-face discussion
Suppliers	• Sustainable Supply Chain Management • Climate Change Response • Information Security and Privacy Protection	• Regular communication and meetings • Performance evaluation • Onsite coaching and inspection • Questionnaires
Business Partners	• Code of Business Conduct and Anti-Corruption • Anti-unfair competition behavior • Information Security and Privacy Protection • Sustainable Supply Chain Management • Product Safety and Quality • Climate Change Response • Energy Management	• Industry alliances • Workshops and seminars • Project cooperation • Questionnaires
Communities	• Corporate Governance • Code of Business Conduct and Anti-Corruption • Information Security and Privacy Protection • Product Safety and Quality • Product Research and Innovation • Product Accessibility • Climate Change Mitigation • Energy Management	• Public welfare activities • Public health promotion events • EHS associations • Questionnaires

Key Stakeholders	Issues of Concern	Main communication mechanisms
Customers	• Product Safety and Quality • Product Research and Innovation • Product Accessibility • Information Security and Privacy Protection • Public Welfare and Charity	• Company email • Formal meetings and visits • Informed consent form • Patient service • JW Therapeutics Hotline
Employees	• Employee Health and Safety • Compliance Employment • Employee Rights and Benefits • Employee Training and Development	• Town hall meetings • Training and performance reviews • Seminars and workshops • Team building • Questionnaires

In 2024, we integrated the results of interviews and conversations with key stakeholders, questionnaires and other forms of research and reidentified and assessed the most material issues for JW Therapeutics with the Board based on our communications with various stakeholders, the strategic planning of the Company and analysis of the market environment. The "2024 ESG Materiality Matrix of JW Therapeutics" was formulated correspondingly, including 8 highly important issues, 10 medium important issues, and 4 general important issues, providing a basis for the Company to formulate and update the ESG strategy.



2024 ESG Materiality Matrix of JW Therapeutics

Degree of Importance	Number	Issue	Category
High Importance	1	Product Safety and Quality	Social
	2	Product Research and Innovation	Social
	3	Information Security and Privacy Protection	Social
	4	Occupational Health and Safety	Social
	5	Product Accessibility	Social
	6	Compliant Employment	Social
	7	IP Protection	Social
	8	Employee Rights and Benefits	Social
Medium Importance	9	Sustainable Supply Chain Management	Social
	10	Corporate Governance	Governance
	11	Code of Business Conduct and Anti-Corruption	Governance
	12	Risk Management	Governance
	13	Anti-unfair Competition Behavior	Governance
	14	Waste Management	Environmental
	15	Employee Training and Development	Social
	16	Emissions Management	Environmental
	17	Industry Communication and Cooperation	Social
	18	Energy Management	Environmental
General Importance	19	Water Consumption	Environmental
	20	Packaging Material Management	Environmental
	21	Public Welfare and Charity	Social
	22	Climate Change Mitigation	Environmental

1.3 Internal Control and Risk Management

In response to the complex and ever-changing external environment and the uncertainties inherent in the commercialization process of products, JW Therapeutics has established a comprehensive management framework and implemented effective measures to continuously enhance the Company's internal control and risk management capabilities, ensuring safe and stable operations and development. We also consistently enhance our internal control and the risk management system by conducting annual risk assessments and governance, formulating the internal audit scope based on the change of the internal and external risk environment and business operation, and adopting and implementing proactive improvement measures based on audit findings.

1.3.1 Internal Control and Risk Management Structure

JW Therapeutics has established a sound internal control and risk management structure involving various levels of employees from different departments, guided by the *Corporate Risk Management Policy* and the *Regulations on Internal Audit*. The Audit Committee serves as the Company's highest decision-making body for risk management, playing a dominant role in internal control and risk management. Led by the Chief Executive Officer ("CEO") and supported by the Internal Audit Department, the Risk Management Committee consists of members who serve as heads of core departments including Legal & Compliance, Finance, Quality, Medical Affairs, Business, Manufacturing Operations, and Human Resources. The Committee holds regular meetings to comprehensively review and discuss annual risk assessment reports, and closely supervises the implementation and execution of risk mitigation measures related to business to ensure the effectiveness and timeliness.

The Risk Management Committee assigns the heads of relevant departments to form a risk management working group to be responsible for the specific organization and implementation of risk management. Through cross-sectoral collaboration, the working group promotes risk-specific governance work to execute specific objectives. In addition, we also engage third-party professional teams to serve as consultants who provide professional recommendations on operational and internal control compliance aligned with HKEX requirements for the Board and the management team.

1.3.2 Annual Risk Assessment and Audit Program

JW Therapeutics conducts an annual risk assessment. Through internal interviews, the department heads identified multi-dimensional risk factors, including market and economic risks, technological risks, compliance risks, ESG and climate-related risks, etc. to ensure the comprehensiveness and accuracy of risk identification. Additionally, combined with the Company's strategic objectives and feedback from interviews with key departments, the identified key risks have been scientifically classified, deeply evaluated, systematically managed, and continuously monitored. For key risks, we have timely completed the rectification measures and ongoing monitoring to ensure timely control and effective mitigation of risks. For climate-related risk management, please refer to *4.1 Climate Change* in this report.

Audit Committee	• Evaluate and supervise the overall risks related to business and operation • Review and approve annual internal audit plan • Review and approve annual risk management and internal control reports
Risk Management Committee	• Lead and oversee the Company's internal control and risk management efforts • Promote the development, enhancement, and operation of the Company's internal control and risk management systems • Review and coordinate the resolution of significant risk management issues • Ensure appropriate structure of each department and supervise the compliance and effectiveness of the ESG working procedure
Internal Audit	• Assist the Board and the Audit Committee to review the adequacy and effectiveness of risk management and internal control • Drive the operation of Risk Management Committee • Independently examine key risks in relation to material controls • Conduct audit programs and supervise rectification measures
Legal & Compliance	• Establish legal and compliance policies in company management and governance • Provide trainings on code of conduct and medical compliance • Review specific compliance issues in healthcare and business • Identify risks in commercial operation and provide consulting services on operation and management strategies

Internal Control and Risk Management Structure

1.4 Business Ethics

JW Therapeutics strictly adheres to principles of professionalism, fairness, and integrity, firmly rejecting any form of bribery, corruption or fraudulent behavior. We have developed and strictly enforced a series of pharmaceutical industry compliance policies, including the *Company Code of Conduct*, *Regulations on Anti-Money Laundry, Anti-Fraud and Anti-Bribery* as well as policies regarding *Corporate Sponsorship*, *Corporate Donations* and *Service Fee Arrangements*, ensuring the Company's business ethics standards are clear and followed.

Laws and regulations that we strictly adhere to include but are not limited to:
Civil Code of the People's Republic of China *Anti-Unfair Competition Law of the People's Republic of China* *Anti-monopoly Law of the People's Republic of China* *Advertising Law of the People's Republic of China* *Medicinal Product Administration Law of the People's Republic of China*
Internal policies that we developed include but are not limited to:
Company Code of Conduct *Standard Operating Procedure ("SOP") for Corporate Sponsorship* *SOP for Company Donations* *SOP for FEE-for-Service* *SOP for Meal, Travel, and Hospitality* *SOP for Company Stamp Management* *Regulations on Personal Data Privacy* *Regulations for Contract Management* *Regulations on Intellectual Property Rights* *Regulations on Conflicts of Interest and Declaration* *Regulations on Anti-Money Laundry* *Regulations on Anti-Fraud* *Regulations on Anti-Bribery* *Regulations on Internal Audit* *Code for Securities Transactions by Relevant Employees*

1.4.1 Compliance Culture

In terms of employee Code of Conduct, we recognize that conducting business in an ethical and compliant manner is the forefront of all commercial activities. To ensure that we deliver better medicines in a responsible way, we require every employee to adhere to the *Company Code of Conduct* and values. We organize annual *Company Code of Conduct* trainings for all employees, with the core contents of identifying, reporting, and avoiding any actual or potential corrupt behavior. Any violation of the *Company Code of Conduct*, especially involving corruption and fraud, will result in disciplinary action based on the event severity.

In respect of the business ethics on supplier side, JW Therapeutics also upholds strict ethical standards to suppliers. We clearly stipulate with suppliers who have signed standard supply agreements that they must adhere to the Company Code of Conduct and sign the Compliance Statement, which explicitly outlines the commitment to anti-corruption and anti-bribery. To ensure that suppliers understand and adhere to ethical standards, we also provide relevant ethics training materials for reference and learning.

1.4.2 Compliance Training

JW Therapeutics places great importance on the professionalism of the Board and the competence in corporate governance. Annually, we engage external professional consultants and teams to provide professional legal and compliance trainings for directors and senior managers, of which the content includes responsibilities and duties related to company listing. During the Reporting Period, we conducted trainings on director responsibilities and duties for all Board members and executives. In case of Board members change, compliance training would be provided for new Board members to ensure that our Board members and executives fully understand their responsibilities and duties.

JW Therapeutics highly values the integrity and honesty of its employees. We provide compliance trainings, the content of which includes laws and regulations, anti-fraud and anti-corruption, for all employees through online channels. To strengthen our culture of integrity, we provide annual training on the *Company Code of Conduct*, medical compliance, and business ethics (the "Annual Training") for employees, agents, consultants, and third-party service personnel. The Annual Training aims to help our employees distinguish between ethical and unethical behaviors and make the right decisions in any situation. The Annual Training is divided into six sessions, each of which includes lectures on specific topics and quizzes. Completion of all six sessions and passing all tests are required to complete the entire training. All employees completed and passed the annual compliance training.



Six Sessions of Medical Compliance and Business Ethics Code of Conduct Training

Given that JW Therapeutics operates in the highly regulated biopharmaceutical industry, we have established comprehensive compliance control systems and processes for specific and critical departments in our daily operations to ensure better compliance with regulations.

1.4.3 Whistle-blowing Channel

JW Therapeutics has set up a reporting mailbox and encourages all employees to report on any inappropriate business conduct via email, phone or anonymous letter. We are committed to taking strict measures to address any violations of business ethics seriously. Additionally, we have implemented whistleblower protection procedures and related policies, along with a series of stringent measures to safeguard the identity and privacy of whistleblowers, protecting whistleblowers from any form of retaliation.

During the Reporting Period, there were no legal cases regarding corrupt practices reported.

1.5 Information Security

As we continuously evolve product commercialization and R&D pipelines, securing information is directly related to the Company's core competitiveness and increasingly important for stakeholders such as investors, patients, customers, suppliers and employees. In this regard, we have strengthened our information security management through formulating a series of internal policies, building sound management systems, clarifying the responsibilities, strengthening data risk prevention and control, and continuously enhancing our information security management capability.

Laws and regulations that we strictly adhere to include but are not limited to:
Cybersecurity Law of the People's Republic of China *Information Security Level Protection Management Measures*
Internal policies that we developed include but are not limited to:
Regulations on Personal Data Privacy *Data Security IT Administrative Regulations of JW Therapeutics* *IT Computerized System Management Measures* *Information Security Management Overview* *Employee IT Information Security Codes* *Information Security Emergency Response Process* *SOP for Information and Data Processing Arrangements* *Information Security Operation and Maintenance Management System* *SOP of NBU Backup System* *SOP of Non-GXP IT Infrastructure* *Privileged Account Audit Management*

We have established an organizational structure that includes the head of IT department, IT information security executive group, IT infrastructure and IT terminal management to strengthen the management of information security. Furthermore, the Company has developed a comprehensive information security management system tailored to its business characteristics and organizational structure to define responsibilities. We have formulated the *Information Security Operation and Maintenance Management System* setting out detailed regulations for network security and server security operation and maintenance management, to ensure the effective implementation of various policies and standards. JW Therapeutics' information system, named "E-nuotongxing", has been certified with Grade 2 Network Security Classified Protection Certification.

During the Reporting Period, we have updated the *SOP of NBU Backup System*, segmenting the Company's network security areas based on security levels and functions and establishing behavioral guidelines for employees regarding information transmission in their daily work, which ensures secure storage, operation, and backup of business data.

In terms of data leakage management, Data Loss Prevention (DLP) system is responsible for the comprehensive management of data risk prevention and control. The prevention management and security alert functions of the system are helpful for IT departments and core business departments to improve the capability to identify and prevent potential data leakage risks, as well as to strengthen control over employee data protection behaviors.

In terms of information transmission behavior management, we have implemented strict management measures, including closing the data transmission interface of computer terminals and controlling access to network storage, ensuring that our employees follow the regulations on information transmission. We have defined specific requirements for data protection, account management, internal file decryption processes, computer viruses, file retention and transmission in our Employee Handbook. At the same time, when employees leave the Company, the information security team will conduct strict reviews of their information transmission behaviors. According to the *Data Security IT Administrative Regulations of JW Therapeutics*, each employee is required to initiate an information security audit when leaving the Company.

During the Reporting Period, no information security or data leakage incidents occurred in JW Therapeutics.

We also prioritize enhancing employees' awareness of information security. During the Reporting Period, we organized online information security protection training for all employees, which focused on daily information and data security, followed by corresponding examinations after the training. During the Reporting Period, a total of 204 employees had participated in information security training during the year, with a training completion rate of 91.17%.

2 BRINGING HOPES FOR CURE

— Enhancing access to CAR-T therapies and health through innovation-driven and quality-centered products

UN SDGs	Topics	Actions
	• Product Research and Development • Product Quality	• Leverage our integrated cell therapy platform to expand into the solid tumor market • Solidify the application of relma-cel in approved indications and expand clinical R&D and innovation of other new products • Establish a quality control process covering clinical R&D, manufacturing, commercialization and approved drug use

As a leading CAR-T therapy biotechnology company, JW Therapeutics is committed to "bringing new hopes for cure" as its mission, striving to provide patients with reliable and assured products. We make every effort to make R&D progress and solidify our leadership in hematological cancers. To guard patients' health, we continuously enhance the quality management system to ensure the quality and safety of our products.

2.1 Product Research and Development

We establish a diverse R&D pipeline, implement standardized product R&D management, strict IP and data privacy management, and develop promising R&D strategies to enable continuous innovation and change. We have complied with health and safety, advertising, labelling and privacy and remedies laws and regulations that materially affect us in relation to the products and services we provide during the Reporting Period.

Laws and regulations that we strictly adhere to include but are not limited to:
International Conference on Harmonization ("ICH") standards Good Clinical Practice ("GCP") Good Manufacturing Practice ("GMP") Good Pharmacovigilance Practice ("GVP")

Internal policies that we developed include but are not limited to:

Standard Operating Procedures ("SOPs"), including:

- Regulatory, Research and Development ("RR&D")
  - Clinical quality assurance & risk management
  - Pharmacovigilance
  - Clinical operations
  - Data management
  - Biostatistics
  - Regulatory affairs
  - Medical affairs and insights
  - Clinical development
  - Medical communications
  - Translational research
  - Portfolio and project management
- Data Integrity
  - *Data Integrity & Record Retention*
  - *Internal Transfer of Clinical Data and Results*
  - *External Transfer of Clinical Data and Results*
  - *Study Quality Oversight*
  - *Data Management Quality Control*
  - *Lifecycle Management of RR&D Procedural Documents*
  - *Lifecycle Management of Computerized System in RR&D*
- Clinical Ethics
  - *Development, Review, Approval and Maintenance of ICF*
- Information and Privacy Protection
  - *Information Technology Computerized System Management Regulations*
  - *JW Therapeutics Data Security IT Management System*
  - *Employee IT Information Security Codes*
- IP
  - *Regulations on Intellectual Property Rights*

2.1.1 R&D Strategy

JW Therapeutics has embedded its patient-first and innovation-driven commitments into research and development, with the aspiration to fulfill the unmet medical needs while alleviating socio-economic burdens for access to CAR-T cell therapy. In this regard, our R&D considerations incorporate weightings of current situation of therapies and socio-economic burdens.



Consideration Factors of Our R&D Strategy

Specifically, we focus on the following R&D strategies to solidify our current product development progress and expand the applications:

Solidify our leadership in hematological cancers by continuing to develop Carteyva® for earlier lines of treatment

In January 2024, the National Medical Products Administration of China ("NMPA") accepted our supplemental New Drug Application ("sNDA") relating to Carteyva® as a treatment for adult patients with r/r MCL. In August 2024, The NMPA approved this sNDA relating to Carteyva®. This is the third proven indication of Carteyva®, which has been granted breakthrough therapy designations and priority review, becoming the first cell therapy product approved in China for the treatment of patients with r/r MCL.

The transformation of high-tech achievements has received authoritative recognition

On February 18, 2024, Carteyva® was announced in the first batch of 2024 as a proposed Shanghai High-Tech Achievement Transformation Project by the Science and Technology Commission of Shanghai Municipality. The Company's independent innovation capabilities have received authoritative recognition.

Further expand new indications of relma-cel in hematology disease

Our approach to developing Carteyva® indications involves expanding its applications for patients with relapsed or refractory large B-cell lymphoma ("r/r LBCL") after frontline treatment. We commenced patient enrollment in the related clinical trial in November 2024, and the preliminary data have shown superior efficacy and safety profile. Furthermore, the Breakthrough Therapy Designation ("BTD") application submitted in October 2024 for this indication has been recognized by regulatory authorities.

Expand relma-cel use into autoimmune diseases, as well as clinical development of other new products

Autoimmune diseases are a critical part of JW Therapeutics' strategy. We are committed to maximizing the clinical value of relma-cel, and look forward to providing a new treatment option for patients with autoimmune diseases.

In April 2023, we received the IND clearance from the NMPA of China for a registered clinical trial of relma-cel in patients with moderately or severely refractory systemic lupus erythematosus ("SLE"). We completed patient enrollment by the end of 2024 and are conducting a long-term follow-up currently, advancing relma-cel as a potential treatment with innovation, safety and efficiency for patients with moderately or severely active SLE. We believe that the Company may be able to secure a first-mover advantage in the highly promising market through development of such therapy.

Leverage our integrated cell therapy platform to expand into the solid tumor market

We aim to achieve breakthroughs in the field of solid tumors through deep collaborations with world-leading cell therapy partners and thus ultimately serve more patients. We believe that there is an opportunity to use these technologies as a platform for multiple new cell therapies that can be applied across diverse solid tumor indications.

Based on rights that we in-licensed from 2seventy bio in the second half of 2022, we commenced clinical development of cell therapy products directed to melanoma-associated antigen A4 ("MAGE-A4") in 2024.

We have established an integrated cell therapy innovation and commercialization platform with cross-disciplinary expertise to expedite our research and development strategies. This platform supports R&D for multiple indications, enabling efficient programs from discovery to early clinical stages.



Our Integrated Cell Therapy Innovation and Commercialization Platform

2.1.2 Product Pipeline

Guided by our clear R&D strategy and rigorous product development processes, we are committed to expanding our current pipelines and developing new technologies to improve the efficacy and safety of CAR-T cell therapy.

As of the end of the Reporting Period, our robust and differentiated cell-based immunotherapy pipeline is as follows. For more detailed information of each product candidate, please refer to "Our Product Pipeline" in the 2024 Annual Report of JW Therapeutics.

The following chart summarizes the current development status of our products and product candidates that are intended for treatment of hematologic malignancies and autoimmune diseases:

	Product	Target	Indication	Commercial Rights	Pre-clinical	Phase I	Pivotal / Phase II/III	NDA	Marketed	Partner
Hematologic Malignancies	JWCAR029 / Relmacabtagene Autoleucel (relma-cel)[1]	CD19	3L LBCL	Mainland China, Hong Kong, Macau*						
			3L FL	Mainland China, Hong Kong, Macau*						
			r/r MCL	Mainland China, Hong Kong, Macau*						
			Front Line LBCL	Mainland China, Hong Kong, Macau*						
			2L LBCL	Mainland China, Hong Kong, Macau*						
			3L ALL	Mainland China, Hong Kong, Macau*						
			3L CLL	Mainland China, Hong Kong, Macau*						
	JWCAR129 [2]	BCMA	r/r MM	Mainland China, Hong Kong, Macau*						
Other	JWCAR029 / Autoimmune [3]	CD19	SLE	Mainland China, Hong Kong, Macau*						

Abbreviations: LBCL = large B-cell lymphoma; FL = follicular lymphoma; MCL = mantle cell lymphoma; ALL = acute lymphoblastic leukemia; CLL = chronic lymphocytic leukemia; MM = multiple myeloma; NHL = non-Hodgkin lymphoma; SLE = systemic lupus erythematosus.

* Mainland China, Hong Kong and Macau refer to Mainland China, Hong Kong (China) and Macau (China), respectively.

1. Relma-cel is based on the same chimeric antigen receptor ("CAR") construct as the product lisocabtagene maraleucel (Breyanzi or lisocabtagene or liso-cel) of Juno, which was approved by the U.S. Food and Drug Administration ("FDA") in February 2021.

2. JWCAR129 is based on the same CAR construct as Juno's product orvacabtagene autoleucel (orva-cel).

3. SLE is a chronic autoimmune disease characterized by the production of autoantibodies and abnormal B-lymphocyte function.

The following chart summarizes the current development status of our product candidates that are intended for treatment of solid tumors:

	Product	Target	Indication	Commercial Rights	Pre-clinical	Phase I	Pivotal / Phase II/III	NDA	Marketed	Partner
Solid Tumors	JWATM204 [1]	GPC3	HCC	Mainland China, Hong Kong, Macau, Taiwan, and member countries of ASEAN*						EUREKA
	JWATM214 [2]	GPC3	HCC	Mainland China, Hong Kong, Macau, Taiwan, and member countries of ASEAN*						Lyell EUREKA
	JWATM203 [1]	AFP	HCC	Mainland China, Hong Kong, Macau, Taiwan, and member countries of ASEAN*						EUREKA
	JWATM213	AFP	HCC	Mainland China, Hong Kong, Macau, Taiwan, and member countries of ASEAN*						Lyell EUREKA
	JWTCR001	MAGE-A4	various solid tumors	Mainland China, Hong Kong, Macau*						seventybio
	JWCAR031	DLL3	SCLC	Mainland China, Hong Kong, Macau*						Bristol Myers Squibb

Abbreviations: HCC = hepatocellular carcinoma; NSCLC = non-small cell lung cancer; AFP = alpha-fetoprotein; GPC3 = glypican-3; r/r = relapsed or refractory; HAS = hepatoid adenocarcinoma of the stomach; MAGE-A4 = melanoma associated antigen A4; DLL3 = Delta-like ligand 3.

* Mainland China, Hong Kong, Macau and Taiwan refer to Mainland China, Hong Kong (China), Macau (China) and Taiwan (China), respectively.

1. JWATM204 is in a Phase I investigator-initiated trial in China. Eureka's products based on the CAR constructs underlying JWATM203 and JWATM204 are currently in Phase I/II trials in the US conducted by Eureka under an IND application. In November 2021, the FDA granted Fast Track Designation to Eureka's counterpart to JWATM203 for the treatment of hepatoblastoma ("HB") and HCC in pediatric patients, as well as "rare pediatric disease designation" for the treatment of HB. In February 2022, the FDA granted Orphan Drug Designation to Eureka's counterparts to JWATM203 and JWATM204.

2. Developing using Lyell technology.

As of the end of the Reporting Period, our core product Carteyva® had been approved by the NMPA for three indications:

- Adult patients with r/r LBCL after two or more lines of systemic therapy;
- Adult patients with r/r FL in which a relapse occurs within 24 months of second-line or higher systemic treatment;
- Adult patients with r/r MCL after two or more lines of systemic therapy including BTKi.

2.1.3 Standardized Product R&D Management

A robust quality management structure is the cornerstone for enhancing R&D innovation and assuring R&D data reliability. Our standardized product development procedure throughout R&D process has guaranteed our pipeline expansion efficiency and effectiveness. The general process consists of four main stages:

Overview of the Product Development Process

To ensure the compliance of our R&D activities, we have implemented the clinical quality management system ("cQMS") to standardize quality management practices across all clinical trials and guarantee compliance with regulated RR&D activities.

In 2024, we established multi-level, multi-directional and optimized cooperation with external partners based on our short-, medium-and long-term development strategy. We further enhanced our in-house R&D capability by establishing a new autoimmune disease R&D team, aiming to expand and solidify relma-cel use in autoimmune field based on our matured manufacturing process, quality control and sophisticated clinical research of CAR-T treatment.

Our Competitiveness of Relma-cel Use in Autoimmune Diseases

Furthermore, we regularly organize training programs and activities in RR&D both on our Veeva training platform and offline, aiming to improve employees' skills and abilities as well as foster their scientific research enthusiasm.

R&D training activities

JW Therapeutics recognizes that continuous skill enhancement is crucial to develop the talents within the RR&D team. In this regard, we hold trainings for employees on an ongoing basis, in accordance with external regulations and internal quality requirements. We conduct continuous trainings on updated regulations and SOPs via the Veeva Training System, in which the content includes the instructor-led New Hire Onboard Training and RR&D Learning Seminars covering clinical development topical issues and experience sharing activities. In July 2024, we conducted a one-day orientation training for 4 new employees. During the Reporting Period, we held 2 RR&D learning seminars, 9 RR&D onboarding training sessions organized by CQA&RM for new employees, and 19 Veeva system document training sessions.

2.1.4 IP Management

With the expansion of product pipelines, we strengthen IP management to lay a solid foundation for protecting R&D and innovation results. We have formulated the *Intellectual Property Rules* and the *JW Therapeutics Intellectual Property Guidelines*, which clearly stipulate the IP management system, patent application and maintenance, and standardize the reporting procedures for trade secrets, copyrights and trademarks. The Company's IP team discusses major IP issues and strategic decisions. We have established an Intellectual Property Committee to clarify the basic responsibilities of employees at all levels in relation to IP. During the Reporting Period, the Committee held its first meeting in January 2024, engaging in in-depth discussions on future IP protection strategies and patent application strategies, which laid a solid foundation for the Company's IP efforts during the Reporting Period.

After entering the commercialization stage, JW Therapeutics has continuously put forward higher requirements for innovation result management and established the following IP management strategies to further support innovative development.



Our IP Protection Strategy

We have carried out many IP protection measures to further protect the interests of the Company and stakeholders. All employees must sign the *Confidentiality Agreement* attached to the labor contract at the time of entry, which specifies the definition of IP rights and the basic duties of employees in respect of IP rights. Besides, we also appointed professional IP counsel to participate in the maintenance of IP in the early stages of R&D and technological innovation, as well as to provide legal and technical support for external cooperation.

As of the end of the Reporting Period, we had 2 utility models approved, 5 invention patents approved, 8 patent applications and 196 invention patent licenses and patent applications introduced from our partners. We also obtained 87 trademarks registered with the China National Intellectual Property Administration ("CNIPA"), and 110 trademarks registered in Hong Kong and Macau.

2.1.5 R&D Data and Privacy Protection

In our pursuit of guarding health through innovative solutions and reliable products, our scientific research standard is guided by high standards of clinical ethics and information integrity.

R&D Data Protection

JW Therapeutics has established various SOPs related to data integrity to ensure information security and compliance as the R&D data that we receive, generate and store requires solid information management. We also utilize the Veeva application system and Managed File Transfer ("MFT") applications for digitalized clinical documentation management and clinical data storage, which enable real-time monitoring and management of the quality of clinical trials, and enhance efficiency.

Data protection measures

We implemented strict data protection measures to protect our products and research achievements and prevent data breaches:

- Built firewalls and online behavior management devices at various sites and enabled advanced protection functions, such as Internet Protocol Suite ("IPS").
- Implemented restrictions on portable storage devices, preventing all office computers from using portable storage devices.
- Established a data leakage prevention system to monitor employee behavior in the Company's sensitive data transmissions.
- Conducted security assessments and set up a web security firewall to prevent application data leakage.
- Deployed MFT applications in JW Therapeutics server for exchanging clinical data internally and externally to ensure the security and efficiency of data transfer.

Privacy Protection

We are committed to protecting the privacy of those who entrust us with their personal information during our research and development.

Privacy protection measures
• For each trial, the expected benefits and potential risks of participating are clearly communicated to the participants through the sign-off of the Informed Consent Form ("ICF"). • We ensure our patients' right to be informed about the whole trial process, including the withdrawing options. • Patients' personal information will be anonymized before uploading or reporting to clinical database to ensure their privacy. • The biobanking and bioanalysis of patient samples (for the purpose of monitoring their safety and efficacy) are consented before enrollments. • Follow the GCP guidance for these samples' chain of custody and interrogation using validated methods.

2.2 Product Quality

JW Therapeutics consistently places great importance on product quality and liability. We emphasize the R&D and manufacturing quality management by establishing a robust quality monitoring system and management structure, endeavoring to foster a quality culture, thereby securing a stable supply of high-quality products and bringing hopes to more patients.

Quality is our lifeline and is every employee's responsibility

We implement and enforce Regulations and Standards throughout our daily work

We are committed to delivering quality products to patients

Our Quality Policy

Laws and regulations that we strictly adhere to include but are not limited to:
Good Laboratory Practice ("GLP") Good Clinical Practice ("GCP") Good Manufacturing Practice ("GMP") Good Supply Practice ("GSP")
Internal policies that we developed include but are not limited to:
Quality manuals Quality management policy Quality standards, batch records, forms, plans, programs, reports, logbooks, etc.

2.2.1 Quality Management System

JW Therapeutics follows the concept of "Quality by Design" and has established a quality management system that exceeds both Chinese and international pharmaceutical standards and regulations, covering the entire life cycle of pharmaceuticals, including clinical, R&D, manufacturing process, commercialization, and approved drug use. In view of the features of CAR-T products, we also cover the whole process of quality management from the manufacturing stage to medical application.

We have established a quality management structure consisting of senior management, functional departments and analytical method development teams, clarifying the scope of responsibilities of each department. This lays a solid foundation for quality management system and process, ensuring a successful quality control process.

In accordance with relevant quality management laws and regulations, we continuously optimize our internal quality management policies to standardize processes, such as production operations, product quality control, and quality standard supervision. As of the end of the Reporting Period, we have kept a total of 2,047 quality management documents, including various policies, procedures, quality standards and forms.



Quality Management System Structure

Quality Management Policies and Guidelines

JW Therapeutics continued to strengthen the construction of quality management system. During the Reporting Period, we continuously enhanced several management optimization measures in the following areas:

Production and distribution traceability management system
• Manage and control each production step through electronic batch records of Manufacturing Execution System ("MES"); ensure the consistency of patient identity; carry out the management of materials, warehouses, main batch reports and online system
End-to-end quality management of cell therapy products
• Carry out quality management from the use end to the distribution end in medical institutes to control the whole-process quality of cell therapy products and fulfill product quality responsibility

2.2.2 Quality Control across the Whole Chain

We have established a quality control procedure across the entire chain, encompassing clinical R&D, manufacturing process, commercialization and approved drug use to ensure product safety, effectiveness and quality during research, manufacturing, operation and utilization.



In terms of quality improvement of manufacturing process, we test the stability of the equipment in the development stage and customize the equipment program in combination with specific manufacturing control to meet the requirements of different product development. In addition, we actively explore the application of integrated manufacturing processes and achieve process control consolidation and simplification in the development stage of new product processes to improve manufacturing efficiency and shorten manufacturing time. During the Reporting Period, we have completed the establishment of a series of Contamination Control Strategy ("CCS") documents, which involved a comprehensive assessment of contamination control elements throughout the entire production process across hundreds of documents, including those related to plant facilities, utility systems, equipment, personnel, materials, product containers and seals, supplier management, cleaning and disinfection, products and processes, viral safety, and monitoring systems. Risks were identified, and improvement measures were formulated, continuously enhancing the aseptic assurance level of the company's product manufacturing. Furthermore, we focused on quality optimization in production cost control, refining operational process management to reduce production costs while maintaining the same level of aseptic assurance.

In terms of drug quality testing, we have developed highly standardized sample monitoring specifications and product release standards, based on the disease progress and the particularity of CAR-T products. The quality management department regularly monitors the drug manufacturing environment, including the monitoring of suspended particles, floating bacteria, settling bacteria, surface microorganisms of objects, surface microorganisms of personnel and other environmental conditions, to ensure the safety of the drug manufacturing environment. The quality management department also needs to carry out 18 inspection projects for drug release, including biochemical testing, physical and chemical testing, and microbial testing. During the Reporting Period, we optimized the training process of various drug testing, further clarified the precautions of testing operation steps, and effectively guaranteed the operational compliance of testing personnel. As the Marketing Authorization Holder ("MAH") for our products, we conduct annual self-inspections and monitoring of the entire quality inspection process at the Suzhou manufacturing site in accordance with relevant regulations to ensure compliance in the inspection process and reliability of product quality. In June 2024, we underwent a product sampling inspection conducted by the Shanghai Institute for Food and Drug Control, and the results were qualified.

Suzhou manufacturing site received an on-site GMP compliance inspection

From September 23 to September 26, 2024, Center for Inspection of Jiangsu Medical Products Administration and Suzhou Industrial Park Market Bureau conducted a 4-day on-site GMP compliance inspection at JW Therapeutics Suzhou manufacturing site. The audit results showed no major defects, and the inspection department fully recognized JW Therapeutics' quality management efforts. JW Therapeutics will continue to improve its quality management system, strive for excellence, and provide patients with high-quality products.

During the Reporting Period, local drug regulatory authorities and market supervision authorities strengthened their quality supervision and management of cell therapy practices carried out by medical institutions. The JW Therapeutics' Quality department and CAR-T consultants, with the support of the Sales department, presented the Company's process for managing cell collection procedure and product infusion at the hospital end to local drug regulatory authorities and market supervision authorities. The achievements in quality control process development were praised and recognized by the relevant regulatory authorities.

In addition to our strict internal quality control procedures, we also accept third-party quality inspection and audits to ensure that we meet product quality standards.

Quality Inspection

- JW Therapeutics is subject to pre-approved manufacturing site inspection, development site inspection and GMP inspection of regulatory authorities to prove the effectiveness of the quality management system
- During the Reporting Period, JW Therapeutics attended the credit rating assessment of pharmaceutical manufacturers by Shanghai Pharmaceutical Quality Association for the third time, and was rated as A Rank with the score of 86.36. We have received an A-level rating for three consecutive years, consistently earning recognition for our corporate credit

Quality Audit

- JW Therapeutics conducts regular quality audits on various production and inspection functions, including operational standardization, record accuracy and record compliance. Corresponding rectification measures are formulated timely based on the audit results

Quality Inspection and Audit Measures

2024 年度上海市药品生产企业综合信用风险等级评估

上海市药品生产企业综合信用风险等级

评 估 报 告

企业名称：上海药明巨诺生物科技有限公司
风险类别：高风险
企业分类：高风险 MAH
报告编号：ASHB3662400000059
信用等级：A
信用评分：86.38 分

报告出具单位：上海正信方晟资信评估有限公司
报告制作日期：2024 年 10 月 31 日

Credit Rating Assessment of Pharmaceutical Manufacturers in Shanghai

We have established a comprehensive product recall and traceability mechanism. To enhance our ability to respond to and handle product quality emergencies, we conduct regular drills to evaluate the effectiveness of the recall system. We will consider any new laws, any regulations, any changes of laws and regulations or any changes during the product cycle that may affect recall effectiveness or any changes of product marketing lines and other factors when designing simulated recall programs, identifying their influence on recall effectiveness. During the Reporting Period, JW Therapeutics did not have any product recalls due to safety or health reasons.



Product Recall Process

Product Recall Drill

In August 2024, JW Therapeutics Shanghai conducted a recall drill for our cellular therapy product, relma-cel. The total duration of this recall drill was 7 hours and 36 minutes, and the total time frame for completion met the requirements for a Level 1 recall (within 24 hours). The time frame and accuracy rate of each sub-step met the design requirements of the recall drill plan and the effectiveness of communication between Shanghai JW Therapeutics (MAH) and Suzhou JW Therapeutics (the CMO factory), between Shanghai JW Therapeutics and primary distributors, as well as between primary distributors and downstream secondary distributors, DTP pharmacies (channels), including logistics providers, has been verified, thus demonstrating that the recall system for relma-cel can work effectively.

Drug Tracking System

To ensure the management and traceability of relma-cel on the commercial operation end and to meet the compliance requirements of regulatory authorities, we added tracing code module based on the original identity digital system, improving the management after the release of relma-cel injection products.

The module possesses the capability to gather drug tracing data, and uploads the data to the tracking platform for basic data management of the tracking code, ensuring the quality and safety of the whole process of drug manufacturing and management by means of information technology, preventing counterfeit and inferior drugs from entering legal channels, so as to accurately realize the traceability and recall of drugs in the regulatory system.

2.2.3 Quality Culture

The Quality-centered principle is deeply embedded in our corporate value, and we are committed to creating an atmosphere where all staff prioritize product quality. We continue to construct advanced quality culture, formulate quality management assessment system, and actively carry out various training activities, comprehensively improving the quality awareness of employees.

Quality Assurance Responsibility

We require all employees to strictly comply with the quality management related regulations including GMP and internal policies including *Quality Manuals*. To motivate employees to take quality responsibility, we incorporate performance indicators related to quality management into employee performance assessment to further strengthen quality assurance.

Quality Training

We attach importance to the improvement of quality awareness in employees and carry out quality trainings to strengthen employees' knowledge of rules and regulations, as well as the detail of product quality control. We formulated *Personnel Training and Qualification* and established a full process quality training system covering the company level to the job level, and improved quality awareness through new employee training, on-the-job continuous training, special training and commercialization training.

New employee training	On-the-job training	Special training	Commercialization training
• GMP training for new employees • Professional training program	• Annual training • Periodic training • Ad-hoc training • External training • Documentation training	• Clinical production training • Cell immunotherapy and gene therapy technology background and key points	• Commercialized production training • Regulatory training for post-market changes

Quality Training System

2024 Annual Quality Training

During the Reporting Period, the company-level annual quality training covered 11 topics, including *Pharmaceutical Laws and Regulations*, *GMP and Related Appendices and Guidelines for the Production Quality Management of Cell Therapy Products (Trial)*, *Quality Policy and Quality Objectives*, *EHS Biosafety*, *Data Integrity*, *Basic Microbiology Knowledge and Aseptic Behavior Standards*, *Personnel Hygiene*, *CAR-T Product Process Knowledge Sharing*, *Deviation Process and Case Analysis*, *Change Management and Case Analysis*, and *Risk Management*. All annual training sessions for 2024 have been completed. The training encompassed various themes such as legal regulations, biosafety, personnel hygiene and aseptic behavior, and data integrity, thereby strengthening employees' knowledge and behavioral habits.

In addition to company-level training, each department also carried out department-level annual training based on its own situation. All department-level training sessions for 2024 have been completed.

3 PATIENT FIRST

— Adhere to patient-first and bring hope to patients through innovative and accessible therapies

UN SDGs	Topics	Actions
	• Patient-centered Ecosystem • Pharmacovigilance • Responsible Marketing	• Insist on the "6P Strategy", strengthen the communication and collaboration with various stakeholders, explore Innovative payment methods, and benefit more patients • Implement pharmacovigilance and drug risk management to ensure patient safety • Improve the level of responsible marketing management and achieve sustainable development of commercialization

Adhering to the value of "Patient First", JW Therapeutics strives to build a patient-centered cell immunotherapy ecosystem, bringing hope to patients in China and around the globe with innovative and high-quality cell immunotherapy products, and leading the healthy and standardized development of China's cell immunotherapy industry.

3.1 Patient-centered Ecosystem

Laws and regulations that we strictly adhere to include but are not limited to:

Diagnosis and Treatment Standards for the Whole Process Management of Relma-cel Treatment of B-NHL
Guidelines for Quality Management of Cell Therapy Products (Trial)
Guiding Principles for Clinical Application of Relmacabtagene Autoleucel injection (2021 Version)
Technical Specification for Clinical Application of Chimeric Antigen Receptor T Cell Therapy Drugs (2022 Edition)
Experts' Consensus on the Management of CAR-T Therapy in the Context of SARS-CoV-2 Infection (2024 Version)

Internal policies that we developed include but are not limited to:

SOPs, including:

- *Medical Science Liaisons — Role and Capability*
- *Medical Science Liaisons — Governance and Compliance*
- *Medical Information Enquiry*

JW Therapeutics has developed a patient-centered "6P Strategy" that involves key stakeholders in the whole treatment process of CAR-T therapy, including Patients, Payors, Physicians, Providers, Partners and Policymakers. We put in efforts in the management and control of all aspects of the CAR-T therapy, aiming to bring our patients quality therapy and thorough care. Meanwhile, we actively address the challenges in the process of product commercialization, continue to improve the affordability for payors, and collaborate with medical institutions and business partners to make greater contributions to the development and promotion of CAR-T therapy and provide more support for the health and well-being of patients.



Patient-centric "6P Strategy"

3.1.1 Safeguarding Patients and Payors

Caring for Patients

As a pioneer of CAR-T therapy, JW Therapeutics strictly follows the CAR-T treatment process and has assigned dedicated teams accountable for managing every stage of the entire process to safeguard patients. We conduct rigorous process management, quality control and long-term follow-up with patients and physicians to ensure treatment results and experience.

Quality Control

- Our client service team strictly manages the apheresis and infusion process through quality control measures including confirmation of physician qualifications, medical device check, temperature control and time node control to safeguard patients

Process Management

- We implement strict management throughout the entire treatment process, utilizing a full-process unified Chain of Identity (COI) system to prevent treatment results from being affected by human errors
- We trace blood samples throughout the process of product manufacturing and transportation to ensure product quality and safety

Customer Service

- After the treatment, we conduct long-term follow-up with patients and physicians to understand patient needs and enhance their treatment experience
- We have established a customer service hotline to promptly respond to inquiries and complaints arising after commercialization. During the Reporting Period, we did not receive any complaints

Measures to Safeguard Patients

We strictly implement the full-process risk control during the apheresis process, developing independent operational process standards and guidelines for different collection models to ensure the safety of raw materials and patients.



Full-process Risk Control of Autologous Leukocyte Apheresis ("APH") Collection

Improving Affordability for Payors

JW Therapeutics actively explores solutions to address the commercialization challenges of innovative products. We continue to advance the commercialization process of Carteyva® to improve the accessibility and affordability of the product, thus benefiting more patients.

We consistently expand our collaboration with partners from various sectors and have assisted in establishing a multi-layer medical care system by listing Carteyva® in local governmental complementary medical insurance programs, commercial insurance products and innovative payment platforms to enhance the insurance coverage of our products. During the Report Period, we continued to establish partnerships with commercial insurance companies, innovative payment platforms and philanthropic foundations to facilitate the inclusion of Carteyva® in more insurance plans, thus improving the affordability for payors. Furthermore, we actively cooperate with the National Healthcare Security Administration to formulate the medical insurance catalogue thereby increasing the accessibility of our products to patients in the future.



Multi-layer Protection System

3.1.2 Empowering Providers and Physicians

Selecting and Certifying Providers

JW Therapeutics strictly implements medical institution entry and certification procedures, ensuring that our products are only provided through quality-certificated hospitals and DTP pharmacies. We certify medical institutions to administer Carteyva® through the following steps:



Medical Institution Certification Procedure

Additionally, we have established a comprehensive product storage management process for DTP pharmacies including guidelines and requirements for assessment standards, storage conditions, access and maintenance process, equipment maintenance and temperature check to ensure product quality during storage.

As of the end of the Reporting Period, we have completed assessment and training for 140 medical institutions in China, certifying them for the use of Carteyva®.

When a medical institution becomes our eligible partner, we will list it in the COI system for full product traceability and management. We conduct re-certification of eligible medical institutions every two years through process audits, on-site inspections and capability training to ensure the quality of their services and patient safety.

Communicating and Collaborating with Physicians

Physicians play a key role in advancing CAR-T therapy, standardizing treatment processes and reporting adverse reactions. JW Therapeutics actively advances its communication and collaboration with physicians, striving to benefit more patients with CAR-T therapy.

We have established a professional in-house Medial Science Liaisons ("MSLs") team to communicate with physicians, providing comprehensive medical support throughout the CAR-T treatment to ensure effective use of our products and better treatment results.

JW Therapeutics assisted partner hospitals to change APH collection volume

In August 2024, we updated the production process requirements regarding the volume of APH collections from patient. To enhance the understanding of the updated parameters and processes among medical staff at partner hospitals, the patient services team from JW Therapeutics' Commercial department visited key hospitals across various regions. They provided professional training to the relevant medical personnel and organized dedicated seminars to facilitate a quicker adaptation to the new collection requirements. Through the efforts of the patient services team, hundreds of cell-collecting and nursing staff have been trained, reducing of collection risks and significantly enhancing the quality of services benefiting patients.

3.1.3 Cooperating with Business Partners

JW Therapeutics is dedicated to bringing hope to more patients. We have formed strategic cooperation with partners who share our mission, working together to benefit more patients and promoting the standardized and high-quality development of our industry.

Access Evaluation	Distribution Management	Training and Qualification
• We conduct comprehensive evaluation of our distributors regarding transportation conditions, storage capacity, temperature control, etc. to formulate a reliable supply chain in compliance with the GMP requirements • During the Reporting Period, Shanghai Pharma KDL is continuously engaged as our national distributor, providing professional delivery services for patients	• Together with our partners, we have explored a safe and effective commercial operation management system equipped with nationwide distribution network, advanced cold chain delivery system and experienced DTP pharmacies, which accelerates the access and treatment process of Carteyva® and therefore benefits more patients	• We attach great importance to the distribution network capabilities, providing training and dry runs for our partners. We conduct essential training on commercial product operational process and transportation quality, covering distributors at all levels and DTP pharmacies' staff, clarifying our quality requirements • We require our partners to establish training records, and only registered personnel who have completed the training are allowed to operate our products

Business Partner Management Measures

3.1.4 Assisting with Policymakers

JW Therapeutics understands that CAR-T therapy represents a new treatment process distinct from any other treatment currently approved in the Chinese market. Adhering to our vision of "Becoming an Innovation Leader in Cell Immunotherapy", we closely collaborate with government and regulatory agencies and actively participate in the formulation and implementation of policies, regulations and industry standards. We are committed to contributing to the establishment of best practices in CAR-T therapy and leading the standardized, high-quality, and sustainable development of the cell immunotherapy industry in China.

Participation in Industry Standards Formulation

JW Therapeutics insists on providing insights and recommendations on the regulations and standards of cell immunotherapy. During the Reporting Period, we have participated in the formulation of a number of policies and sector standards of cell therapy and CAR-T products, contributing to the healthy development of the industry.

Ensuring the smooth and efficient import of R&D materials is crucial for advancing R&D innovation in the cell therapy industry. To address the bottlenecks in importing materials for R&D, JW Therapeutics actively participated in regulatory research and provided insights and recommendations on the entry of specialty items for biopharmaceutical enterprises from the business and industry perspective, assisting the regulatory authorities in introducing and optimizing relevant policies and measures.

During the Reporting Period, JW Therapeutics participated in the development of industry standards

- *Experts' Consensus on the Management of CAR-T Therapy in the Context of SARS-CoV-2 Infection*
- *Guidelines for Quality Management of Cellular Therapeutic Drugs in Medical Institutions*
- *Guidelines for the Production Inspection of Cell Therapy Products*

Inclusion of Carteyva® in Product Recommendation Catalogs and Industrial Pilot Policies

As a pioneer of the cell immunotherapy enterprise, JW Therapeutics closely collaborates with the local government and regulatory departments including Shanghai Customs, Shanghai Municipal Administration for Market Regulation and Shanghai Municipal Commission of Commerce to promote the development and implementation of industry regulations. Our core product Carteyva® has been listed in multiple product recommendation catalogs, accelerating the commercialization process and benefiting more patients.

JW Therapeutics has been listed in the "white list" for the entry and exit of the biopharmaceutical industry

We have actively promoted the development of policies related to the import of special items in the biopharmaceutical sector. Since 2019, JW Therapeutics' core products have been listed in several whitelists for the import of cell therapy industry materials and finished pharmaceutical products and JW Therapeutics has become a pilot unit for related joint regulatory mechanisms, including:

- The "White List" for Entry of Biopharmaceutical R&D Items in Pudong New Area
- The "White List" for Entry of Special Items for Biopharmaceutical R&D in Pudong New Area
- Shanghai Joint Supervision Mechanism for Entry and Exit of Special Goods for Cell Therapy
- Suzhou Area's "White List" for Import of Biopharmaceutical R&D Goods (the Yanyida 2.0)
- Pilot Enterprise for "Vacuum Packaging and Other High-Tech Goods Inspection and Control Model" at Pudong Customs
- First-Class Pilot Enterprise for Sharing and Mutual Recognition of Risk Assessment Results of Special Items in the Yangtze River Delta Region at Nanjing Customs
- First Batch of Pilot Enterprises on the "White List" of Entry of Special Items in Suzhou Industrial Park

Carteyva® has been included in Products Recommended Catalog

- *Suzhou Biopharmaceutical and Health Industry Innovative Products*
- *Shanghai Innovative Products Recommended Catalog*
- *Shanghai Biopharmaceutical Innovative and Outstanding Medical Product Catalog*

JW Therapeutics will continue to practice its corporate vision and mission, playing a leading role in the industry to help create a better regulatory environment, accelerate product innovation and ultimately benefit more patients.

3.2 Pharmacovigilance

Laws and regulations that we strictly adhere to include but are not limited to:

Pharmaceutical Administration Law of the People's Republic of China
Guideline on Good Pharmacovigilance Practices ("GVP")
Good Clinical Practice
Provisions for Adverse Drug Reaction Reporting and Monitoring
E2A: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting, International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use ("ICH")
E2B (R3): Clinical Safety Data Management: Data Elements for Transmission of Individual Case Safety Reports (ICSR), ICH
E2D: Guideline for Post-approval Safety Data Management: Definitions and Standards for Expedited Reporting, ICH
The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products, WHO

Internal policies that we developed include but are not limited to:

SOPs, including:

- Pharmacovigilance Management
- Management of Individual Case Safety Report ("ICSR")
- Management of ADR Monitoring and Reporting
- Setup and Operation of Safety Management Team
- Setup and Operation of Drug Safety Committee
- Safety Signal Management
- Regulatory Safety Inquiry Management
- China Periodic Safety Report Preparation and Submission
- Development and Management of Drug Risk Management Plan

Pharmacovigilance involves the detection, understanding and prevention or minimization of the severity of adverse reactions caused by investigational products. As a responsible marketing authorization holder, we have defined the organizational structure, personnel responsibilities, safety information processes, management system, and operational standards of pharmacovigilance. Our pharmacovigilance system enables us to collect, monitor, assess, and evaluate information on adverse events related to our products. By adhering to the pharmacovigilance management framework, we ensure compliance with relevant pharmacovigilance regulations.



Pharmacovigilance Management Structure

Drug Safety Committee

- The Drug Safety Committee, under the direct supervision of the Chief Executive Officer, is responsible for all decisions on material safety matters that may have a substantial impact on the well-being of patients or subjects
- Conducts major risk assessments, major or emergency drug incidents management, risk control decisions and other major issues related to pharmacovigilance

Medication Safety Management Team

- Responsible for safety planning and periodic and in depth safety review of emerging data that could impact subjects/patients safety
- Composes and reviews the safety material, identifies potential risk, creates, agrees, proposes and documents action plans for important potential risk or important identified risk
- Consults, communicates and escalates reported safety signal/potential safety issue to Drug Safety Committee
- Manages data of the product safety profile

Pharmacovigilance Team

- The pharmacovigilance team is responsible for implementing regular pharmacovigilance activities
- Routinely reviews the safety data and responsible for signal validation; reports suspected safety signal to Medication Safety Management Team
- Takes risk minimization or mitigation actions per product risk management plan

Head of Pharmacovigilance

- Ensures compliance of adverse drug reactions monitoring and reporting
- Oversights the identification, assessment and control of drug safety risks and ensures the effective implementation of risk control measures
- Responsible for the management of drug safety information communication and ensures timely and effective communication
- Ensures that the communication channels within the Marketing Authorization Holder ("MAH"), and with the drug regulatory authorities and the adverse drug reaction monitoring organizations are unblocked

Heads of Functional Departments

- Build up good communication and coordination mechanism with pharmacovigilance department, and ensure the smooth implementation of pharmacovigilance activities
- Ensure the relevant pharmacovigilance responsibilities are reflected in the Department Description and Job Descriptions
- Ensure the department staff complete the mandatory pharmacovigilance related SOP training

Pharmacovigilance System Responsibility

Our Pharmacovigilance Department has developed a Risk Management Plan and Risk Evaluation and Mitigation Strategies ("REMS") to ensure that our products can only be assessed from accredited hospitals and that all relevant healthcare professionals ("HCPs") are properly trained and qualified to distribute, infuse and administer products and to manage potential adverse effects.

Realizing the importance of our employees in the pharmacovigilance system, we carry out regular training on monitoring and reporting of adverse reactions that covers all employees to help them understand what is adverse drug reaction ("ADR") and how to report ADRs and the requirements of the reporting time limit, which clarifies the value and indispensability of pharmacovigilance.

During the Reporting Period, we published the *2023 Pharmacovigilance Annual Report*, which provides detailed information on pharmacovigilance activities conducted, including but not limited to individual adverse reactions, submission of regular safety reports, monitoring of safety signal and risk assessment. In addition, we prepared and submitted the annual Development Safety Update Report ("DSUR") and Periodic Benefit-Risk Evaluation Report ("PBRER") of relma-cel based on clinical data and post-marketing safety data, which provide analysis and evaluation of the safety and efficacy of relma-cel to ensure that the expected benefits to patients outweigh the identified and potential risks of the product.

3.3 Responsible Marketing

Laws and regulations that we strictly adhere to include but are not limited to:
The Advertising Law of the People's Republic of China *Anti-Unfair Competition Law of the People's Republic of China*
Internal policies that we developed include but are not limited to:
SOPs, including: • Promotional Material Review • Non-promotional Material Review • Corporate Communications

We strictly adhere to the applicable laws and regulations of the places in which we operate during the process of promotion and marketing. We have established a set of strict SOPs regarding responsible marketing to prevent any exaggerated or false advertising, ensuring the compliance of our marketing activities.



Our Efforts for Responsible Marketing

During the Reporting Period, we did not receive any complaints or legal actions related to marketing.

4 ECO-FRIENDLY DEVELOPMENT

— Pursuing environmental goals to protect our planet

UN SDGs	Topics	Actions
	• Climate Change • Environmental Management • Resource Management • Emissions and Discharge Management • Waste Management	• Identify climate-related risks in the context of the Company's business and the development of industry • Propose and take measures to mitigate the climate-related risks identified • Regularly inspect and maintain water supply facilities and equipment • Establish a complete energy management system • Implement modular management in laboratories and manufacturing sites and adopt a series of green office energy-saving measures to reduce operational energy consumption in response to the "dual carbon" goals • Strictly classify and manage waste gas, wastewater and waste from laboratories and production for centralized treatment • Full lifecycle traceability of waste and full process digital management • Strictly enforce the standardized management and disposal of hazardous waste classification

JW Therapeutics consistently adheres to the concept of green development and actively responds to the national call for building a resource-conserving and environmentally friendly society. We actively explore innovative actions to combat climate change by integrating green strategies into daily operations, continuously enhancing environmental management capabilities, increasing investment in environmental protection, implementing energy-saving and consumption-reduction requirements, and widely promoting and executing environmental awareness initiatives. These measures aim to minimize negative impacts on the ecological environment and contribute to the construction of ecological civilization.

4.1 Climate Change

Amid increasing global attention on the impacts of climate change, achieving carbon neutrality has become a common goal for nations and international organizations. To effectively combat the complicated challenges posed by climate change, JW Therapeutics has systematically identified and assessed climate-related risks with reference to our development strategies and industry characteristics, and integrated climate actions into environmental management, actively adopting sustainable practices in operations.

4.1.1 Governance

We built a hierarchical ESG governance structure with clear responsibility delineation. The structure is led by the Board, with the Risk Management Committee and the ESG Working Group collaborating with each other. The Risk Management Committee takes leading responsibility in identifying climate risk changes, formulating mitigation and adaptation measures, and reporting them to the Board on a regular basis. In addition, the ESG Working Group is responsible for the implementation of relevant measures to escort the sustainable development of the Company.

Board

- Highest decision-making and governing body regarding climate issues
- Responsible for setting the Company's sustainability direction and climate targets
- Overseeing of the risk management of climate-related issues
- Regularly reviewing the effectiveness of Company's climate management methods, including targets, goals and action plans

Risk Management Committee

- Identifying, assessing, and monitoring climate change-related risks
- Developing and implementing risk mitigation and adaptation plans
- Regularly evaluating the effectiveness of measures to combat climate change, and reporting to the Board

ESG Working Group

- Taking strong and practical measures to effectively alleviate and combat the impacts of climate change
- Collaborating across departments to drive the implementation of climate actions and continuously monitoring the progress and execution of established targets
- Providing timely feedback to the Risk Management Committee

Climate-Related Risk and Opportunity Governance Structure of JW Therapeutics

4.1.2 Strategy

JW Therapeutics followed the framework of TCFD's disclosure standards and referred to the potential climate change scenarios described in the latest Assessment Report of the United Nations Intergovernmental Panel on Climate Change ("IPCC"). We have identified the physical risks and transition risks that the Company may encounter during the operation. Considering the characteristics of the Company's business and the nature of the industry, we formed the following list of physical and transition risks, covering descriptions of the identified risks and their impacts on the Company's operation along with the response measures.

Climate Change Risks	Risk Description	Response Measures
Climate-related physical risks		
Acute Risks	• The natural disasters (such as typhoons and floods) may cause damage to the Company's assets and equipment, affect the production and operational stability of JW Therapeutics, increasing costs in operation • A decline in transport capacity due to natural disasters and extreme weather may reduce the timeliness of the production transport and infusion of the Company's products, potentially leading to losses in reputation, finances, and patient health	• Establish a disaster early warning mechanism and alert all employees in time through internal communication when extreme weather event occurs • Conduct regular routine inspections of sites and laboratory equipment • Develop an emergency response plan for extreme weather to enhance the capacities to respond to and manage emergencies

Climate Change Risks	Risk Description	Response Measures
Chronical Risks	• Increased probability of extreme weather such as high temperature caused by long-term climate change threatens the health and safety of employees, increases subsidies for high temperature and insurance investment, leading to an increase in labor costs	• Establish an extreme weather warning mechanism to resist the negative impacts of prolonged extreme weather and ensure employee health and safety • Conduct occupational health prevention work related to extreme weather by EHS department and publish response methods in internal publications
Climate-related transition risks		
Policy and Legal Risks	• With the international community's adherence to the *United Nations Framework Convention on Climate Change* and the continuous improvement of domestic regulations related to carbon emissions and trading, the Company will bear stricter responsibilities in climate-related information disclosure • Investment in mitigating risks associated with relevant policies and laws may subject the Company to pressure from rising operational costs	• Track and understand the latest climate-related and carbon emission laws, regulations and polices to ensure that the Company could take timely corresponding measures • Actively explore potential opportunities in the carbon emission trading market to drive low-carbon transformation and capitalize on green development opportunities for the Company
Market Risks	• Changes in the supply and demand of goods, products and services caused by the transition to a low-carbon economy may push up raw material costs, exerting pressure on JW Therapeutics' operating costs	• Continuously improve supplier risk assessment and management • Collect and analyze raw material pricing trends in the global markets to grasp market dynamics accurately
Reputation Risks	• If stakeholders perceive the Company's poor performance in climate action, it could affect JW Therapeutics' market reputation and increase the difficulty of raising capital	• Strictly comply with the requirements on enhancing climate information disclosure • Actively improve the communication with stakeholders to ensure the timely and accurate information transmission

Measures Taken to Combat Climate Change

To achieve more in energy saving and emissions reduction and combat climate change effectively, we are committed to improving energy measurement system, enhancing energy saving practices during operation and production, as well as promoting eco-friendly business. Through these measures, we firmly implement energy saving and emissions reduction actions to reach sustainable development goals.

Laboratory Operation

- Shanghai Jinchuang R&D laboratory decommissions underutilized laboratory equipment, such as biosafety cabinets, to reduce energy consumption
- Suzhou MFG Module 1 implements scheduled shutdowns, turning off air conditioning, equipment, and lighting to lower energy usage while meeting commercial production requirements
- Based on experimental needs, air conditioning systems and lighting are turned off when no experiments are scheduled

Production Process

- Suzhou QC and ATS laboratories control the temperature and humidity of clean rooms, reducing energy consumption while maintaining GMP production standards
- Shanghai Jinchuang R&D laboratory's vector process platform reduces supply and exhaust air volume by 20% and adjusts air conditioning temperature and humidity ranges to meet basic experimental needs, thereby reducing energy consumption

Green Office Actions

- Shanghai Wison Center office sets timed air conditioning activation and shutdown according to work hours
- Suzhou manufacturing site office adopts a centralized office mode, turning off air conditioning, lighting, and office equipment in unused areas
- In office areas and meeting rooms, lights are turned off when not in use

Energy Saving and Emissions Reduction Measures Taken by JW Therapeutics

Energy-saving Signs in JW Therapeutics' Office Areas

4.1.3 Risk Management

We have established comprehensive procedures for the identification, analysis, and assessment of climate-related risks. Relying on the Risk Management Committee and ESG governance framework, we collect and consolidate information related to the Company's risks and management. Based on this information and its impact on business development and financial performance, potential climate risks that could hinder departmental objectives are identified and their likelihood evaluated, thereby establishing climate-related risk assessed levels. For significant identified risks, response strategies and risk resolution plans are developed based on the evaluation of the effectiveness of the existing internal control system. Additionally, reasonable risk control targets are determined, serving as the basis and tracking indicators for conducting climate-related risk management work.

Risk Identification, Assessment and Management Process

4.1.4 Metrics and Target Tracking

We have set specific energy consumption and GHG emissions targets in 2021 to quantify the results achieved in combating climate change. Since then, we evaluate our environmental performance against the targets annually, and are committed to continuously reducing the negative impact on the environment. During the Reporting Period, JW Therapeutics effectively implemented energy saving and emission reduction measures, achieving remarkable results. Compared to 2021, the overall energy consumption intensity had reduced by 84%, and GHG emissions intensity had reduced by 86% in 2024.

Performance Metrics

Energy Consumption	Unit	2022	2023	2024
Indirect Energy Consumption				
Total purchased electricity	kWh	6,828,230.00	6,249,599.26	5,150,645.01
Total purchased steam	ton	4,089.90	4,451.90	3,967.60
Comprehensive Energy Consumption[2]				
Direct energy consumption	MWh	0	0	0
Indirect energy consumption	MWh	11,107.82	10,907.97	8,209.00
Total energy consumption	MWh	11,107.82	10,907.97	8,209.00
Energy consumption intensity	MWh/RMB 10,000 revenue	0.76	0.63	0.52
GHG Emissions[3]				
Scope 1	tCO_2e	99.32	88.40	83.93
Scope 2	tCO_2e	5,105.81	4,883.06	3,938.40
Total GHG emissions	tCO_2e	5,205.13	4,971.46	4,022.33
GHG emissions intensity	tCO_2e/RMB 10,000 revenue	0.36	0.29	0.25

2 During the Reporting Period, we did not engage in direct energy consumption. Indirect energy consumption includes the purchased electricity and steam. The comprehensive energy consumption calculation refers to the *General Rules for Calculation of the Comprehensive Energy Consumption* (GB/T 2589–2020) issued by the State Administration for Market Regulation.

3 Scope 1 GHG emissions are derived from refrigerant consumption; Scope 2 GHG emissions are derived from the consumption of purchased electricity and steam. The 2024 electricity emission factor refers to the electricity CO_2 emission factors of *Announcement on the Release of the 2022 Electricity CO_2 Emission Factors* issued by the Ministry of Ecology and Environment of the People's Republic of China and the National Bureau of Statistics on December 20, 2024.

Targets Tracking

Key Performance Indicator ("KPI")	Base Year (2021)	2025 Target	2024 Performance
Comprehensive energy consumption intensity	3.23 MWh/RMB10,000 revenue	40% decrease compared to 2021	0.52 MWh/RMB10,000 revenue 84% decrease compared to 2021
GHG emissions intensity (Scope 1 & Scope 2)	1.78 tCO_2e/RMB10,000 revenue	40% decrease compared to 2021	0.25 tCO_2e/RMB10,000 revenue 86% decrease compared to 2021

4.2 Environmental Management

Laws and regulations that we strictly adhere to including but not limited to:
Environmental Protection Law of the People's Republic of China *Energy Conservation Law of the People's Republic of China* *Law of the People's Republic of China on Environmental Impact Assessment* *Environmental Protection Tax Law of the People's Republic of China*
Internal policies that we developed including but not limited to:
EHS Management System, involving regular assessment and follow-up rectification actions to standardize EHS compliance management
Our management systems:
JW Therapeutics integrated the EHS Compliance Management System and EHS-related standard operating procedures into daily work based on the requirements of ISO 14001 environmental management system and safety production standardization third-level management system

JW Therapeutics strictly abides by environmental laws and regulations. We have established the environmental management system based on the laws and regulations and have compiled corresponding guidance documents to ensure the effective implementation of environmental management measures.

To fully implement environmental protection measures in all departments, JW Therapeutics has set up an independent EHS Committee, which consists of core leaders from production and R&D departments. It works closely with all departments to promote the implementation of EHS management requirements. EHS meetings are held regularly to conduct discussions and evaluations to ensure that environmental management and EHS indicator performance are always up to date. Furthermore, we established a partnership with a professional third-party EHS regulatory consulting provider to assist us in keeping up with EHS-related legal updates and revising the SOPs accordingly.

Before the launch of every new construction and renovation project, compliance with environmental laws and regulations will be assessed, and environmental assessment and necessary permits will be obtained from the environmental authorities prior to the commencement of the project. We have earnestly fulfilled our reporting obligations under the Pollutant Discharge Permit and truthfully submitted the annual report of pollutant discharge permit. During the Reporting Period, we had no external environmental pollution incidents, and no environmental penalties incurred, which indicated our high attention to environmental protection and that our tangible actions had been conducted.

4.3 Resource Management

Natural resources are vital to human living and are equally indispensable in medical research, development and production. We are committed to reducing our impacts on the planet through efficient and circular use of water and packaging materials, and ensuring responsible sourcing, consumption, production and disposal.

4.3.1 Water Management

As the water crisis becomes more prevalent, water resources management has raised widespread concern globally. JW Therapeutics strictly adheres to the laws and regulations of each place in which we operate, and constantly enhances our water resource management. All water used by JW Therapeutics comes from the municipal water supply system and is used mainly for daily operation and production. During the Reporting Period, our total water consumption was 19,291.00 m^3, which reduced 22.50% compared to 2023.

We set a medium and long-term water conservation target in 2021, with the aim of driving companies to continuously strengthen the water resource management, effectively improving the water use efficiency. With our relentless efforts, the water consumption intensity in 2024 has reduced by 77% compared to 2021.

Target Tracking

Water Consumption	Base Year (2021 Performance)	2025 Target	2024 Performance
Water consumption intensity	5.30 m^3/RMB 10,000 revenue	20% decrease compared to 2021	1.22 m^3/RMB 10,000 revenue 77% decrease compared to 2021

We have implemented a series of water conservation measures in our production and daily usage to maintain a high rate of water utilization.

Production water supply inspection

- To ensure stable water supply for production, we pay high attention to water supply check and routinely engage experts to carry out a complete and detailed examination on the water supply system

Daily water conservation awareness promotion

- We focus on enhancing the employees' awareness of water conservation and guide them to develop good water-saving habits by displaying signages in public areas, etc., jointly contributing to the conservation of water resources

4.3.2 Packaging Material Management

JW Therapeutics evaluates materials used in our production and value chain strictly, and proactively looks for opportunities to reduce packaging materials from sources. We are aware of the influence brought about by packaging materials to the environment, and therefore work with our clients closely to actively recommend and guide them towards more simplified and environmentally friendly packaging materials. For example, we encouraged our clients to replace traditional packaging materials with recyclable plastic plates to reduce the environmental impact of unnecessary overpackaging. Besides, JW Therapeutics also works actively with packaging material suppliers to explore and promote the use of green packaging materials. We selected packaging materials that are in line with the concept of sustainable development to further reduce the environmental burden of packaging materials. During the Reporting Period, we mainly used cartons and plastic as packaging materials and controlled the amount of packaging materials strictly. The total amount of cartons and plastic packaging materials used in 2024 was 63.87 kg and 2.77 kg, respectively.

Target Tracking

Packaging Material Consumption	Unit	2022 Performance	2023 Performance	2024 Performance
Total packaging material consumption	kg	46.97	79.09	66.64
Packaging material consumption intensity	kg/RMB10,000 revenue	0.0032	0.0045	0.0042

4.4 Emissions and Discharge Management

JW Therapeutics is highly conscious of the air emission, wastewater and solid waste generated in our operations. We strive to minimize the amount of air emission, wastewater and solid waste, improve recycling rates and actively fulfill our obligations to minimize environmental impacts, aiming at eco-friendly production.

Laws and regulations that we strictly adhere to including but not limited to:
Atmospheric Pollution Prevention and Control Law of the People's Republic of China *Water Pollution Prevention and Control Law of the People's Republic of China* *Law of the People's Republic of China on the Prevention and Control of Environment Pollution Caused by Solid Wastes* *Comprehensive Sewage Discharge Standard*
Internal policies that we developed including but not limited to:
Sewage Treatment System Operation and Maintenance Regulations *Hazardous Waste Disposal Procedures of Zhangjiang* *Hazardous Waste Disposal of Suzhou* *General Waste Disposal*

4.4.1 Air Emissions Management

JW Therapeutics has implemented strict air emission treatment measures to reduce pollutant emitted from our laboratories and manufacturing sites. Our main air pollutant is non-methane hydrocarbon ("NMHC") generated from alcohols during the experimental and production process and air emission discharged from the wastewater treatment plant. Air emission generated from production process is strictly categorized and then collected by the efficient ventilation systems and treated by physicochemical processes. In addition, supervision will be strengthened through online monitoring and regular testing to ensure that the concentration of exhaust gas emissions meets the national standards and environmental safety is maintained. The laboratory's waste gas is treated through secondary activated carbon filtration and adsorption before being discharged in compliance with standards through a chimney. During the Reporting Period, our total NMHC emissions reached 7.91 kg, decreased by 85.80% compared with 55.86 kg in 2023. The primary air pollutants generated by the wastewater treatment plant's emissions are hydrogen sulfide and ammonia, both of which complied with the emission standards during the Reporting Period.



Waste Gas Treatment Tower and Exhaust Gas Outlet in Suzhou Manufacturing Site of JW Therapeutics

Processing Methods	• NMHC is collected by the ventilation systems and treated by activated carbon adsorption devices before ultimately discharged from the exhaust system in compliance with standards • 90% of organic air emission collected by gas collectors is disposed by the activated carbon adsorption device, the remaining 10% is discharged through the exhaust cylinder • For the air emission discharged from the wastewater treatment plant, we use a low-temperature plasma device for treatment before discharge
Supervisory Measures	• Our manufacturing sites enter into annual commissioned testing agreements with third parties to conduct quarterly testing of organized and unorganized exhaust gas pollutants and issue inspection reports
Improvement of Devices	• In order to dispose waste more efficiently, Suzhou manufacturing site began to change the activated carbon in the exhaust cylinder twice a year instead of once a year

Air Emissions Management Procedures

4.4.2 Wastewater Management

JW Therapeutics strictly adheres to the wastewater discharge standards of the regions in which it operates and has established strict internal policies to ensure that cleaning wastewater discharges generated from production are effectively managed. We set up industrial wastewater treatment plants in all sites and follow the prescribed processes to manage. After treatment, production wastewater is entirely reused without being discharged externally. Public auxiliary wastewater is cooled through cooling ponds and other measures before being discharged in compliance with standards. Additionally, we have established an online sewage monitoring system to ensure that the concentration of pollutant discharge consistently remain within the limits of the emission standards. Detailed wastewater treatment procedures are implemented as follows:

Precautions	• Clinical manufacturing sites examined all the wastewater pipelines in laboratories, identified main pollution sources and factors, and chose more eco-friendly hand cleaner instead of alcohol-based hand sanitizer to reduce the influence of laboratory wastewater on COD
Monitoring	• An online monitoring system for wastewater has been established to collect and upload timely information about key indicators (e.g. COD, ammonia nitrogen, pH rate and flow). The alarm set in the system can be activated under abnormal circumstances to raise staff's attention to avoid excessive discharge
Disposal	• Wastewater from production was disposed in self-built sewage treatment station with measures (e.g. carbon filtration, ultrafiltration, reverse osmosis) to ensure water quality reached the standard of reuse water for reusing in the cooling system. The evaporation residue was handled safely by qualified contractors
System Operation and Maintenance	• Our manufacturing sites will enter into equipment operation and maintenance agreements with qualified third parties and entrust professionals to perform system operation and maintenance to ensure reliable operation of our systems

Wastewater Management Procedures

Wastewater Treatment Plants of JW Therapeutics' Suzhou Manufacturing Site

During the Reporting Period, JW Therapeutics commissioned third-party testing institutions to test the effluent from wastewater treatment plants at the R&D center and manufacturing sites for characteristic pollutants, and all test results complied with national standards.

Performance Metric

Wastewater Characteristic Pollutant Emissions	Unit	2024 Performance
Chemical oxygen demand	kg	485.79
Ammonia nitrogen	kg	18.68
Total nitrogen	kg	14.84
Total phosphorus	kg	2.71
Suspended solid	kg	75.63
Biochemical oxygen demand after 5 days ("BOD_5")	kg	117.12
Volatile phenols	kg	0.36
Formaldehyde	kg	1.09
Total residual chlorine	kg	0.07
Acetonitrile	kg	Not detected

4.4.3 Hazardous and Non-hazardous Waste Management

In terms of hazardous waste management, all manufacturing sites and R&D centers of JW Therapeutics comply with national and local environmental protection laws and regulations, as well as biosafety requirements. In line with industry standards for biopharmaceuticals, all waste generated by P2 laboratories undergoes inactivation treatment. P2 laboratory waste is managed according to the principle of same-level or in-situ inactivation. The waste after inactivation is collected, classified, stored, and transported as hazardous waste, and is handed over to qualified third-party hazardous waste disposal companies for legal and compliant disposal.

Hazardous Waste Management Procedures

We have carried out many hazardous waste disposal trainings, educated all cleaners and hazardous waste management personnel of all departments in hazardous waste management. We also conducted targeted hazardous waste leakage emergency drills for hazardous waste warehouse leaders and transportation personnel.

Laboratory Hazardous Waste Generation Sources Signs and Hazardous Waste Deactivation Areas Signs

In terms of non-hazardous waste management, our non-hazardous waste mainly consists of two categories: general industrial solid waste and office garbage. We have established a set of waste management process for a clean environment and recyclable use. The cleaners are responsible for the daily collection of non-hazardous waste every day. In particular, the general solid waste is sent to a professional third-party waste-disposal contractor for further treatment. Office garbage is transferred to designated garbage recycling stations in bio-industrial parks for centralized collection and disposal.

In terms of waste reduction management, our Suzhou manufacturing site is committed to enhancing material utilization during manufacturing process. By integrating lean manufacturing and operational excellence, we strive to minimize waste generation to the greatest extent possible. Statistical data indicate a year-on-year decline in total waste volume, accompanied by a reduction in waste disposal costs.

In daily operation, we actively promote and implement eco-friendly measures. For example, we encourage employees to use both-sided printing and recycle wastepaper and educate cleaners on garbage sorting and post signs in office space to raise eco-friendly awareness and enhance the efficiency of garbage sorting of all staff. We strictly adhere to related local policies and laws about garbage sorting and set different types of garbage cans within the Company to ensure that all types of garbage are correctly classified and disposed of.

Target Tracking

Waste Indicator	2025 target	2024 performance
Compliant disposal of hazardous waste	100%	100%
Recyclable cartons in general industrial solid waste	100%	100%

Performance Metrics

Emission Performance	Unit	2022	2023	2024
Air emissions				
NMHC	kg	92.46	55.86	7.93[4]
Wastewater				
Total wastewater	ton	17,968.60	20,860.05	20,609.30
Non-hazardous Waste				
Total non-hazardous waste	kg	78,132.20	67,348.14	48,710.00
– Recyclable non-hazardous waste	kg	19,217.20	16,209.40	15,368.00
– Non-recyclable non-hazardous waste	kg	58,915.00	51,138.74	33,342.00
Non-hazardous waste intensity	kg/RMB10,000 revenue	5.36	3.87	3.08
Hazardous Waste				
Total hazardous waste	kg	52,275.55	55,291.09	43,220.46
Hazardous waste intensity	kg/RMB10,000 revenue	3.59	3.18	2.73

[4] The NMHC emissions are calculated based on single sampling test data. The test results are influenced by the operating conditions and instantaneous concentrations at the time of sampling, leading to certain variability in the results.

5 PEOPLE ORIENTED

— Empower employees to provide unlimited power for enterprise development

UN SDGs	Topics	Actions
	• Employment Management • Communication and Care • Employee Development • Occupational Health and Safety	• Establish diverse recruitment methods and channels to attract and retain a wide range of excellent talents • Promote mutual communication between employees and the Company; establish employee appeal channels • Provide employees with various benefits and guarantees, and organize diverse activities • Build a diversified career development channel to provide employees with a variety of growth and promotion paths • Establish a comprehensive EHS management system to create a healthy and safe working environment

We regard talent as a vital asset to the Company and are committed to providing a work environment rich in humanistic care. We cultivate a corporate culture of mutual respect and collaborative growth, ensuring that employees can realize their potential in a harmonious and stable environment, growing together with the Company.

5.1 Employment Management

JW Therapeutics strictly adheres to the relevant laws and regulations of labor management in the People's Republic of China. We consistently refine our internal policies and management systems to guarantee the legality and compliance of our employment practices.

Laws and regulations that we strictly adhere to include but are not limited to:
Labor Law of the People's Republic of China *Labor Contract Law of the People's Republic of China*
Internal policies that we developed include but are not limited to:
JW Therapeutics Employee Handbook

5.1.1 Employment Compliance

We strictly prohibit child labor, forced labor, and other forms of labor abuse. As required in the *JW Therapeutics Employee Handbook*, we carry out identity verification on new hires to avoid employment violations such as child labor, while upholding individual privacy and information security standards. If any breaches occur, the Company will conduct a detailed investigation and implement suitable measures in line with applicable laws, regulations, and internal policies. During the Reporting Period, there was no incident of child labor or forced labor.

We employ diverse recruitment methods and channels to attract a wide range of excellent talents, including online recruitment, campus recruitment, internal referrals, and collaboration with professional headhunting services. We regularly announce job openings to facilitate internal referrals, thereby improving the effectiveness of aligning roles with skilled individuals.

5.1.2 Diversity, Equity, and Inclusion

JW Therapeutics fosters a diverse workforce, ensuring that recruitment processes are free from the impact of race, ethnicity, gender, religion, and other factors, so as to provide equal employment opportunities for employees from different backgrounds. We fully recognize, accept, and value individual diversity and strive to cultivate a culture that is equitable, transparent, diverse, and inclusive. Our commitment to embracing diverse perspectives enriches team inclusivity and fosters creativity among our employees.

JW Therapeutics is dedicated to advancing fair employment practices and maintaining impartiality across all aspects including recruitment, compensation, training, and promotion. Our hiring decisions are based on a comprehensive evaluation of qualifications, skills, and achievements. We treat and respect every employee equally, and have a zero-tolerance policy towards any form of discrimination and harassment. Any employee suffering discrimination or harassment can report to relevant departments. Disciplinary action, up to and including termination, will be taken upon confirmation of such behavior. During the Reporting Period, there was no discrimination or harassment reported.

5.1.3 Number of Employees

As of the end of the Reporting Period, there were 281 full-time employees and no part-time employees in JW Therapeutics. Distribution of employees by gender, age group, region, and function are as follows:



As of the end of 2024, JW Therapeutics' employee voluntary turnover rate was 19.71%.

Social Indicators	Unit	2022	2023	2024
Number of Employees				
Total number of employees	Number of People	528	399	281
By Gender				
Male	Number of People	222	163	115
Female	Number of People	306	236	166
By Age Group				
Below 30	Number of People	150	108	83
30 to 50	Number of People	367	283	195
Above 50	Number of People	11	8	3
By Geographical Region				
Greater China[5]	Number of People	520	397	280
Overseas	Number of People	8	2	1
By Function				
Technical Operations	Number of People	198	139	97
Commercial	Number of People	95	69	49
Quality	Number of People	101	71	49
Medical	Number of People	81	78	48
Support	Number of People	43	33	32
Business Development	Number of People	10	9	6
Voluntary Turnover Rate[6]				
Total employee voluntary turnover rate	%	21.80	17.65	19.71
By Gender				
Male	%	23.48	20.78	20.86
Female	%	20.53	15.50	18.91
By Age Group				
Below 30	%	22.78	17.83	12.57
30 to 50	%	21.05	17.23	22.59
Above 50	%	34.78	31.58	18.18
By Geographical Region				
Greater China	%	21.80	17.65	19.71
Overseas	%	0	0	0

5 Greater China refers to Mainland China, Hong Kong and Macau.

6 Voluntary Turnover Rate = number of employees who voluntarily resigned during the Reporting Period/(total number of employees at beginning of the Reporting Period + number of employees added during the Reporting Period) × 100%. Voluntary Turnover Rate of each category = number of employees who voluntarily resigned in that category/(total number of employees in that category at the beginning of the Reporting Period + number of employees added in that category during the Reporting Period) × 100%.

5.2 Communication and Care

JW Therapeutics is committed to creating a compassionate and supportive work environment, prioritizing effective communication and employee well-being to ensure they feel valued and supported. We routinely host a range of cultural and athletic events to enrich employees' leisure experiences, thereby enhancing their job satisfaction and fostering a stronger sense of belonging within the Company.

5.2.1 Employee Communication

JW Therapeutics actively fosters open dialogue between employees and the Company through a combination of online and offline approaches. These include setting up a culture wall in the workplace and regularly posting monthly e-newsletters to keep employees informed about the Company's vision, mission, and corporate culture. Additionally, we fully respect employee feedback and opinions, providing multiple communication channels and feedback mechanisms to meet employees' willingness and needs to express themselves in different situations, and encourage employees to provide suggestions for our development.

To ensure that the employee rights are fully protected, we have established an employee grievance channel through which anyone can report any violations of personal rights and interests. We would carefully investigate each report, verify the allegations, and take corresponding disciplinary measures against individuals confirmed to have violation behavior, so as to maintain the fairness, transparency, and security of the Company.

5.2.2 Employee Benefits and Care

JW Therapeutics ensures our employees enjoy a wide array of benefits and security measures. In addition to fulfilling mandatory social insurance and housing fund contributions as per relevant national and local regulations, we extend additional benefits including subsidies, commercial insurance coverage, annual medical examinations, paid sick leave, and holiday benefits. These supplementary benefits are designed to support employees in attaining a harmonious work-life balance and fostering a stronger connection with the Company. We have also established various reward and recognition mechanisms for outstanding performance, including setting up talent-retention programs, such as annual bonus plan and sales incentive scheme, to fully acknowledge and reward employees' exceptional contributions.

Exclusive Benefits

- We offer additional benefits to employees, including annual paid holidays, allowances, team-building fund, etc.
- We offer employees festival and birthday celebration benefits on the Company's platform.
- To guarantee the rights and benefits of female employees during the maternity process, we have established a comprehensive maternity leave policy and set up nursing rooms at our operation sites to provide care and protection for female employees returning to the workplace.

Medical Benefits

- We care about the health of our employees and provide them with comprehensive medical benefits, including a medical check-up program, paid sick leave, and commercial health and life insurance. We offer various medical examination facilities and convenient locations for our employees' benefit. In our commitment to enhancing service quality, we have refined medical examination procedures by introducing new items to cater to individual needs.

Talent Incentive Program

- To recognize, reward and share the Company's achievements with our staff, we provide a variety of incentives, recognition, and talent-retention programs, including bonus plan, outstanding contribution awards, etc.

Employee Benefit Program of JW Therapeutics

JW Therapeutics emphasizes the importance of work-life balance and endeavor to offer our employees fulfilling leisure opportunities. We host a variety of engaging activities such as sports clubs, monthly cultural events and regular reunions to promote employee communication and enhance corporate cohesion. These activities not only allow our employees to relax but also promote positive interaction.



Badminton Activities Held by the Company

JW Therapeutics continues to prioritize the well-being of our employees, endeavoring to "anticipate their needs, address their concerns and fulfill their requirements". With the intention to guarantee the physical and mental health of our employees and enhance their work experience, we implement supportive initiatives, offer tailored assistance to those encountering challenges, and ensure that every employee feels valued and supported.

5.3 Employee Development

JW Therapeutics recognize talent as the cornerstone of innovation and progress. By establishing robust pathways for promotion, effective performance management mechanisms and comprehensive training programs, we cultivate an environment conducive to nurturing exceptional individuals. We harness the potential of talents across all levels and fields, fostering mutual growth between our employees and the Company.

5.3.1 Career Development and Promotion Path

We have established a diversified career development channel, offering both management and professional paths to provide equal promotion opportunities for talents in different fields. Alongside transparent promotion opportunities, the Company has also established an internal transfer mechanism applicable to all employees. We regularly advertise internal job openings to facilitate optimal employee-job alignment, ensuring that employees are provided with promotion paths that are consistent with their career plans and personal strengths.



Career Development System

5.3.2 Performance Management

A fair and just performance evaluation system sparks motivation. We refine our performance management system to ensure transparency and fairness in the evaluation process. We provide timely feedback to employees and assist them in defining their career development objectives. We conduct performance evaluations for employees at different intervals in accordance with the Company's internal performance management procedures. At the onset of each year, the Company will set goals together with employees and provide guidance on their development plans. Subsequently, supervisors conduct routine mid-year performance assessments for our staff. During the performance evaluation process, employees initiate self-assessments, which supervisors then appraise alongside feedback garnered from colleagues. Ultimately, performance ratings are confirmed by cross-functional departments.



Performance Management Procedures

5.3.3 Training and Development System

JW Therapeutics always believe that shaping and presenting the personal value of employees is an important component of the overall value of the Company. We offer a well-developed training system and abundant resources to foster their professional growth. Our comprehensive training mechanism consists of three pillars: enabling onboarding excellence, strengthening leadership, and improving organizational effectiveness. It covers various aspects such as onboarding training, leadership training and organizational effectiveness training, offering employees multi-tiered and comprehensive opportunities for training and growth.

Enabling onboarding excellence

We formulate a comprehensive employee orientation program to ensure new employees understand our values and culture:

- New Employee Onboarding Program
- New Employee Orientation ("NEO") Manager Workshop
- Buddy Program

Strengthening leadership

We focus on leadership development and create a variety of leadership related programs:

- Leadership group coaching
- Project management leadership
- New manager growth engine

Improving organizational effectiveness

We offer our staff training in various business skills to improve organizational effectiveness:

- Offsite Strategy Workshop
- Lunch and Learn
- Functional tailor-made programs
- Learning Community

Three Pillars of Training System

Based on the three pillars, we tailor exclusive training programs for employees at different levels, while launching a digital learning platform online to enhance training efficiency and flexibility.

During the Reporting Period, JW Therapeutics achieved a 100% coverage rate for employee training, with an average training duration of 25 hours per employee. Other details regarding employee training are as follows:

Social Indicators	Unit	2022	2023	2024
Percentage of Employees Trained[7]	%	/	/	100
By Gender[8]				
Male	%	42.05	40.85	40.93
Female	%	57.95	59.15	59.07
By Job Grade				
Senior management	%	6.25	2.76	2.49
Middle management	%	23.48	9.52	8.90
Junior management	%	31.06	29.82	23.49
General employees	%	39.21	57.90	65.12
Training Hours per Employee				
Average training hours	hours	17	23	25
By Gender				
Male	hours	17	17	23
Female	hours	17	28	26
By Job Grade				
Senior management	hours	10	22	26
Middle management	hours	10	31	24
Junior management	hours	18	29	24
General employees	hours	23	19	25

7 Percentage of employees trained = total number of employees trained/total number of employees at the end of the Reporting Period × 100%

8 Percentage of employees trained of each category = Employees in that category trained/total number of employees trained × 100%

5.4 Occupational Health and Safety

JW Therapeutics implements the State Council's opinions on the Healthy China Action, strictly adheres to the provisions of *Law of the People's Republic of China on Work Safety*, and actively improves its internal health management policies and mechanisms.

Laws and regulations that we strictly adhere to include but are not limited to:
Law of the People's Republic of China on Work Safety *Regulations of Jiangsu Province on Work Safety* *Regulations of Shanghai Municipality on Safe Production* *Law of the People's Republic of China on Prevention and Control of Occupational Diseases* *Biosecurity Law of the People's Republic of China* *Regulations of Working Environments on Sanitation Management* *Regulations on Supervision of Occupational Health* *Employer's Occupational Disease Hazard Notification and Warning Label Management Standards* *Regulations of Working Environments on Sanitation Supervision Management* *Regulations of Employers on Occupational Health Supervision and Management* *Regulations of Archive Management on Occupational Sanitation*
Internal policies that we developed include but are not limited to:
Health and Safety Policy, as a component of ESG management system
Our management systems include but are not limited to:
Occupational Health and Safety System Biosafety Management System

5.4.1 Risk Control Mechanism of Health and Safety

JW Therapeutics has established a comprehensive occupational health and safety management system encompassing risk assessment, identification of potential hazards, accident management, and emergency response planning for production incidents to ensure the achievement of a zero-accident target, guaranteeing that employees work in a safe and healthy workplace. Since commencing operations over 4 years ago, Suzhou manufacturing site has maintained a zero work injury record. Additionally, we have been honored the Safety Production and Social Responsibility Enterprise Award by the Suzhou Industrial Park for multiple times.

Our Suzhou manufacturing site has established a comprehensive EHS management system and has achieved certification for the Level 3 Safety Production Standardization System. We have implemented a risk classification control and potential hazard identification and management policy. Through matrix management, we identify EHS risks in manufacturing sites and mitigate and eliminate these risks by developing engineering solutions and refining procedural documents. As the primary person responsible for safety production, the General Manager of the manufacturing site acts as the Director of the Safety Committee, with Heads of key functional departments as members of the Committee. The General Manager leads to conduct monthly safety inspections to check the implementation of on-site safety production policy. The Safety Committee reports on implementation status and related data monthly.

To address potential occupational health and safety risks, we have established a risk control mechanism including procedures for risk assessment, potential hazard reporting, hazard monitoring, emergency response, and continuous inspection. Corrective actions are promptly taken for identified risks.



Risk Control Procedures

Being at the forefront of the biotechnology industry, we prioritize specialized risk management in our production operations. In addition to the general risk control process, we have also set up biosafety management mechanism and established the Biosafety Committee. The Biosafety Committee is responsible for supervising safe production and biosafety risk management, regularly carrying out the troubleshooting of biosafety hazards and supervising the rectification, and regularly conducting emergency drills to ensure the implementation of biosafety management. Meanwhile, we have developed the following management mechanisms for laboratory biosafety and chemical safety:



Management Mechanisms of Laboratory Biosafety and Chemical Safety

5.4.2 Daily Management and Awareness Enhancement

We place significant emphasis on occupational health and safety within our organization. Our EHS Committee oversees the daily occupational health and safety of our employees, and enhances their safety awareness through regular safety training and emergency drills outlined in our *Employer Occupational Health Training Program*. Our Occupational Health and Safety ("OHS") training comprehensively covers all aspects of production operations, including general OHS knowledge, laboratory safety, biological safety, hazardous and special equipment use safety. We have equipped all operational sites, including offices and production facilities, with emergency response equipment such as AEDs and air respirators to ensure the safety of personnel entering these locations. Additionally, specialized occupational health and safety training is provided by the Health and Safety Committee to employees engaged in production activities, as well as to contractors and suppliers before their entry into our facilities.

Emergency Equipment in Offices and Manufacturing Sites

Occupational health examinations

- We strictly adhere to national occupational health laws and regulations and have established a comprehensive occupational health management system. Employees in positions exposed to occupational hazards, such as those dealing with chemicals and noise, undergo pre-employment, in-employment and off-employment occupational health examinations.

Vaccination

- The operation process involves blood samples containing single blood-borne pathogenic microorganism such as hepatitis B. Employees exposed to positive samples are provided with hepatitis B antibody testing and vaccination to protect their health.

Emergency drills

- During the Reporting Period, the EHS Committee continued to conduct a series of activities for Safety Production Month, enhancing employees' health and safety awareness. These activities included fire evacuation and firefighting drills, annual safety production emergency drills, infectious leakage response drills, and infectious material leakage drills in hazardous waste areas.

Occupational Disease Prevention Law Awareness Week

From April 25 to May 1, 2024, China observed its 22nd Occupational Disease Prevention Law Awareness Week. This year's theme was "Focusing on Prevention First, Safeguarding Occupational Health." The EHS department shared 60 occupational health points via email with all employees, organized occupational disease injury drills for employees at the laboratory in Zhangjiang, Shanghai, and provided UMU courses on the use of personal protective equipment to all employees in Suzhou and Shanghai laboratory, and other relevant personnel. Additionally, the revised SOPs related to personal protective equipment and occupational health incident emergency management processes became effective.

Safety Production Month Drills

June 2024 marks the 23rd National Safety Production Month in China, with the theme "Everyone Talks About Safety, Everyone Knows Emergency Response: Ensuring Clear Life Channels." To align with this theme and enhance company-wide safety awareness, as well as to improve employees' emergency response and handling capabilities, our Jinchuang R&D laboratory and Suzhou manufacturing site planned and conducted their annual emergency response and handling drills.

On the afternoon of June 26, Suzhou manufacturing site with Biobay Biotech Industrial Park, the park's property management office, and supplier "Tongxinyuan" jointly planned and implemented a comprehensive drill involving hazardous chemical leakage drills, infectious substance leakage drills, and fire evacuation. The exercise simulated emergency scenarios during the delivery and unloading process by the supplier, as well as during a hazardous chemical or infectious substance leakage emergency, focusing on the coordination and collaboration between the Company, the supplier, and the industrial park property office to handle the incidents effectively.

On the afternoon of June 28, Jinchuang R&D laboratory conducted a tabletop exercise and hands-on practice in the PAD office, focusing on the handling process for infectious substance leakage (biosafety). This exercise strengthened employees' emergency handling capabilities, heightened their safety awareness, achieving the expected outcomes.



During the Reporting Period, there was no work-related injuries. In the past three years, there was no fatality due to work.

6 RESPONSIBLE CITIZEN

— Boosting industry development and common prosperity

UN SDGs	Topic	Actions
	• Supplier Management • Industry Cooperation • Charity Activities	• Continuously strengthen supplier lifecycle management to promote sustainable development of the supply chain • Participate in various industry sharing and communication activities to build an industry ecology and lead industry development • Launch patient care activities to enhance the public awareness of major diseases such as tumors, providing strong support for patient treatment.

JW Therapeutics always adheres to a responsible attitude towards business partners and society, actively exploring and leveraging efficient supply chain management, and collaborating closely with partners in the industry to facilitate a sustainable growth of the supply chain.

6.1 Supplier Management

We strictly adhere to laws and regulations, implement comprehensive supplier lifecycle management measures, conduct regular training for suppliers to ensure supplier compliance in all aspects. At the same time, we also attach great importance to the ethics of animal experimentation during the R&D experimental process, ensuring professionalism and standardization through high standards of animal welfare.

Industrial standards that we strictly adhere to include but are not limited to:
Good Manufacturing Practice (“GMP”) Good Laboratory Practice (“GLP”) Good Supply Practice (“GSP”)
Internal policies that we developed include but are not limited to:
Supplier Access Policies *Supplier Code of Conduct* SOP for Supplier Performance Evaluation Supplier Life Cycle Management Supplier Audit Management Supplier Quality Agreement Management Supplier Complaint Management
Our management systems include but are not limited to:
Enterprise Resource Planning (“ERP”) system

6.1.1 Supplier Selection

The Company has established a rigorous supplier screening process for all suppliers during the supplier access phase. We put forward requirements and conduct comprehensive evaluations on potential suppliers from three aspects: due diligence, compliance requirements, and EHS performance, to ensure that the suppliers we collaborate with possess good qualifications and supply capabilities.



Supplier Selection

6.1.2 Supplier Assessment and Quality Management

The Company performs periodical evaluation to assess supplier performance in terms of quality, cost, delivery, risk, service, and EHS. We conduct comprehensive assessments based on two dimensions: the procurement amount and supply risk. Suppliers are categorized into strategic, leveraged, bottleneck, and general types, and corresponding evaluation management strategies are devised for each type. Strategic suppliers are evaluated annually and leveraged suppliers are evaluated every three years. For suppliers whose performance requires improvement based on the evaluation, we will communicate with them and follow up on improvement plans. We uphold zero tolerance for supplier non-compliance and will terminate the cooperation with suppliers who violate the compliance requirements.



Supplier Performance Evaluation Process

In terms of supplier quality management, we have signed quality-related agreements with suppliers of primary production materials. We conduct quality audits on suppliers' quality systems regularly, and review and evaluate the quality management of suppliers annually to ensure their compliance with our quality management requirements.



Supplier Quality Management Measures

In addition to conducting multi-dimensional performance evaluations of suppliers, we also provide regular trainings to suppliers and require mandatory EHS training for all the contractors and suppliers before their entrance into our manufacturing sites to ensure their standardized operation and safe production when they are on site. Due to the special quality requirements of our products, we engage in continuous communication and dialogue with suppliers to continuously enhance their supply capabilities, and facilitate the sustainable development of the supply chain.

6.1.3 Supplier Localization

JW Therapeutics is dedicated to advancing its supplier localization strategy, by promoting the application of key domestic materials in our research and development of products. We conduct comprehensive technical feasibility assessments during the process development stage, aiming to enhance the stable operation of the localized supply chain. This effort not only optimizes production costs but also further improves patient access to drugs.

Supplier Localization Measures

During the Reporting Period, we have completed the China domestic substitution of 21 raw and auxiliary materials, and completed key actions for the localization of the important material Vector, planning to submit the PAS, which is expected to be approved within one year. We continue to advance the localization of key materials and apply them to commercial production, benefiting more patients with high-quality products.

As of the end of the Reporting Period, we had a total of 498 suppliers. The number of suppliers by geographical region is as follows.

Total Number of Suppliers	498
Number of Suppliers in Mainland China	476
Northeast China Region	1
North China Region	55
Northwest China Region	1
Southwest China Region	7
East China Region	399
Central China Region	3
South China Region	10
Number of Suppliers in Hong Kong, Macao and Taiwan, China	5
Number of Overseas Suppliers	17

6.1.4 Animal Welfare

In compliance with the "3R" principles, JW Therapeutics urges our animal testing suppliers to reduce, refine and replace animal use in accordance with the highest ethical and animal welfare standards. We do not conduct animal testing by ourselves, but we maintain regular communications with our animal testing suppliers and conduct verification procedures to ensure the laboratory procedures during all animal testings comply with relevant standards.

During the Reporting Period, we carried out a qualification review of animal testing suppliers, by verifying their laboratory animal use certifications and other qualification materials, and conducting on-site inspections, to further ensure the compliance of animal tests.



The Principles of Reduction, Replacement and Refinement (3R)

Based on the study designs from our in-house and external statisticians, we also refine and reduce animal use as part of our animal welfare practices. Our preclinical and translational researchers are accredited or certified by the American Board of Toxicology, the Regulatory Affairs Professionals Society and other international associations. Our annual auditing of suppliers indicates that their animal laboratories are currently maintaining the accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care ("AAALAC") International, an international standard for animal welfare. We are committed to maintaining professionalism and standardization of animal welfare with our suppliers at all times.

Our certification:

100% The holding rate of AAALAC International accreditation among suppliers' animal laboratories

6.2 Industry Communication and Cooperation

While continuing to promote its own development, JW Therapeutics also strives to help promote the healthy development of the industry with its excellent strength in cell immunotherapy and contributes to the co-prosperity of the industry by actively carrying out clinical communication and participating in the industrial regulation standardization.

6.2.1 Empower Clinical Practice

JW Therapeutics hosted "Promise the Future, Achieve CR" conference

To enhance the standardized clinical application of cell immunotherapy, during the Reporting Period, we established a diverse academic platform domestically and hosted several academic conferences, such as the "Promise the Future, Achieve CR" conference. This event was conducted via an online platform, gathering leading experts in hematologic malignancies to report and discuss the latest advancements and clinical applications of CAR-T cell therapy. JW Therapeutics is committed to providing a platform for communication in CAR-T cell therapy, supporting multiple stakeholders, including medical institutions, industry physicians, and patients, to share treatment experiences.

6.2.2 Build Ecology

To promote scientific regulation and the healthy development of the industry, JW Therapeutics and industry enterprises co-founded the Shanghai Cell Immunotherapy Industry Alliance in 2017, and established the Cell Immunotherapy Quality Management and Research Specialized Committee of Shanghai Pharmaceutical Quality Association in August 2018 with the support of the Shanghai Municipal Health Commission, Shanghai Food and Drug Inspection Institute, Shanghai Pharmaceutical Quality Association and other relevant departments, to build a technical exchange platform for the cell immunotherapy industry.

During the Reporting Period, we continuously participated in the formulation of industry-related standards to promote industry innovation and standard development. As a member organization of associations such as the Chinese Society of Clinical Oncology ("CSCO"), the China Anti-Cancer Association, and the Hematology Branch of the Chinese Medical Association, we actively participated in academic conferences and industry forums, promoting the implementation of cell immunotherapy from clinical guidelines to clinical practice.

The 2nd International Biotechnology Innovation and Investment Conference

From October 21 to 22, 2024, the 2nd International Biotechnology Innovation and Investment Conference was held in the Guangming District of Shenzhen. Focusing on promoting biotechnology innovation and industrial development, the conference aimed to advance the establishment of a biomedical industry hub and high-quality development. As a leading enterprise in innovative drug research and development, JW Therapeutics was invited as a guest in the roundtable dialogue to discuss with industry experts around future development opportunities in the biotechnology industry.

2024 China Medical City Health and Wellness Industry Forum

From November 29 to November 30, 2024, the 2024 China Medical City Health and Wellness Industry Forum, hosted by People's Government of Taizhou, was held at Conference and Exhibition Trade Center of China Medical City. The forum focused on value creation in biotechnology and value investment in the healthcare industry, addressing key industry topics. JW Therapeutics was invited to engage in in-depth discussions with attendees on breaking through barriers in the access and payment methods for innovative biological products, exploring the possibilities of a diversified payment system for innovative biological drugs.

6.3 Philanthropy

On the road to a sustainable future, we have always been committed to the well-being of patients, actively advocating for deepening care and understanding of them from all sectors of society, jointly providing strong support for the treatment of cancer and other major diseases, and bringing hope, warmth and comfort to patients.

"Huirongbao" specific group insurance project

In 2024, JW Therapeutics provided financial support of over RMB60,000 through Hongmian Cancers and Rare Disorders Charity Foundation of Guangzhou to the Chengdu Social Business Integrated Inclusive Health Insurance, "Huirongbao" specific group insurance project. This initiative purchased "Huirongbao" for 1,000 specific individuals in Chengdu, contributing to alleviating the economic pressure on specific group to resist the risks of major diseases such as cancer and rare diseases, as part of the Company's social responsibility.

Appendix I: HKEX *ESG Reporting Code* Index

Subject Areas, Aspects, General Disclosures and KPIs		Index
A. Environmental		
Aspect A1: Emissions		
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to air emissions, discharges into water and land, and generation of hazardous and non-hazardous waste.	Chapter 4.1 Climate Change Chapter 4.4 Emissions and Discharge Management
KPI A1.1	The types of emissions and respective emissions data.	Chapter 4.1 Climate Change Chapter 4.4 Emissions and Discharge Management
KPI A1.3	Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Chapter 4.4 Emissions and Discharge Management
KPI A1.4	Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Chapter 4.4 Emissions and Discharge Management
KPI A1.5	Description of emission target(s) set and steps taken to achieve them.	Chapter 4.1 Climate Change Chapter 4.4 Emissions and Discharge Management
KPI A1.6	Description of how hazardous and non-hazardous wastes are handled, and a description of reduction target(s) set and steps taken to achieve them.	Chapter 4.4 Emissions and Discharge Management
Aspect A2: Use of Resources		
General Disclosure	Policies on the efficient use of resources, including energy, water and other raw materials.	Chapter 4.3 Resource Management
KPI A2.1	Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).	Chapter 4.1 Climate Change
KPI A2.2	Water consumption in total and intensity (e.g. per unit of production volume, per facility).	Chapter 4.3 Resource Management
KPI A2.3	Description of energy use efficiency target(s) set and steps taken to achieve them.	Chapter 4.1 Climate Change
KPI A2.4	Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency target(s) set and steps taken to achieve them.	Chapter 4.3 Resource Management
KPI A2.5	Total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced.	Chapter 4.3 Resource Management

Subject Areas, Aspects, General Disclosures and KPIs		Index
Aspect A3: The Environment and Natural Resources		
General Disclosure	Policies on minimising the issuer's significant impacts on the environment and natural resources.	Chapter 4.2 Environmental Management Chapter 4.4 Emissions and Discharge Management
KPI A3.1	Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.	Chapter 4.1 Climate Change Chapter 4.3 Resource Management Chapter 4.4 Emissions and Discharge Management
B. Social		
Aspect B1: Employment		
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare.	Chapter 5.1 Employment Management Chapter 5.2 Communication and Care Chapter 5.3 Employee Development
KPI B1.1	Total workforce by gender, employment type (for example, full- or part-time), age group and geographical region.	Chapter 5.1 Employment Management
KPI B1.2	Employee turnover rate by gender, age group and geographical region.	Chapter 5.1 Employment Management
Aspect B2: Health and Safety		
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to providing a safe working environment and protecting employees from occupational hazards.	Chapter 5.4 Occupational Health and Safety
KPI B2.1	Number and rate of work-related fatalities occurred in each of the past three years including the reporting year.	Chapter 5.4 Occupational Health and Safety
KPI B2.2	Lost days due to work injury.	Chapter 5.4 Occupational Health and Safety
KPI B2.3	Description of occupational health and safety measures adopted, and how they are implemented and monitored.	Chapter 5.4 Occupational Health and Safety
Aspect B3: Development and Training		
General Disclosure	Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities.	Chapter 5.3 Employee Development
KPI B3.1	The percentage of employees trained by gender and employee category (e.g. senior management, middle management).	Chapter 5.3 Employee Development
KPI B3.2	The average training hours completed per employee by gender and employee category.	Chapter 5.3 Employee Development

Subject Areas, Aspects, General Disclosures and KPIs		Index
Aspect B4: Labour Standards		
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to preventing child and forced labour.	Chapter 5.1 Employment Management
KPI B4.1	Description of measures to review employment practices to avoid child and forced labour.	Chapter 5.1 Employment Management
KPI B4.2	Description of steps taken to eliminate such practices when discovered.	Chapter 5.1 Employment Management
Aspect B5: Supply Chain Management		
General Disclosure	Policies on managing environmental and social risks of the supply chain.	Chapter 6.1 Supplier Management
KPI B5.1	Number of suppliers by geographical region.	Chapter 6.1 Supplier Management
KPI B5.2	Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, and how they are implemented and monitored.	Chapter 6.1 Supplier Management
KPI B5.3	Description of practices used to identify environmental and social risks along the supply chain, and how they are implemented and monitored.	Chapter 6.1 Supplier Management
KPI B5.4	Description of practices used to promote environmentally preferable products and services when selecting suppliers, and how they are implemented and monitored.	Chapter 6.1 Supplier Management
Aspect B6: Product Responsibility		
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to health and safety, advertising, labelling and privacy matters relating to products and services provided and methods of redress.	Chapter 3 Patient First
KPI B6.1	Percentage of total products sold or shipped subject to recalls for safety and health reasons.	Chapter 2.2 Product Quality
KPI B6.2	Number of products and service related complaints received and how they are dealt with.	Chapter 3.1 Patient-centered Ecosystem
KPI B6.3	Description of practices relating to observing and protecting intellectual property rights.	Chapter 2.1 Product Research and Development
KPI B6.4	Description of quality assurance process and recall procedures.	Chapter 2.2 Product Quality Chapter 3.2 Pharmacovigilance
KPI B6.5	Description of consumer data protection and privacy policies, and how they are implemented and monitored.	Chapter 2.1 Product Research and Development

Subject Areas, Aspects, General Disclosures and KPIs		Index
Aspect B7: Anti-corruption		
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.	Chapter 1.4 Business Ethics
KPI B7.1	Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the Reporting Period and the outcomes of the cases.	Chapter 1.4 Business Ethics
KPI B7.2	Description of preventive measures and whistle-blowing procedures, and how they are implemented and monitored.	Chapter 1.4 Business Ethics
KPI B7.3	Description of anti-corruption training provided to directors and staff.	Chapter 1.4 Business Ethics
Aspect B8: Community Investment		
General Disclosure	Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure its activities take into consideration the communities' interests.	Chapter 6.3 Philanthropy
KPI B8.1	Focus areas of contribution (e.g. education, environmental concerns, labour needs, health, culture, sport).	Chapter 6.3 Philanthropy
KPI B8.2	Resources contributed (e.g. money or time) to the focus area.	Chapter 6.3 Philanthropy
Part D: Climate-related Disclosures		
(I) Governance		
The governance body(s) (which can include a board, committee or equivalent body charged with governance) or individual(s) responsible for oversight of climate-related risks and opportunities.		Chapter 4.1.1 Governance
Management's role in the governance processes, controls and procedures used to monitor, manage and oversee climate-related risks and opportunities.		Chapter 4.1.1 Governance
(II) Strategy		
Climate-related risks and opportunities An issuer shall disclose information to enable an understanding of climate-related risks and opportunities that could reasonably be expected to affect the issuer's cash flows, its access to finance or cost of capital over the short, medium or long term.		Chapter 4.1.2 Strategy
Business model and value chain An issuer shall disclose information that enables an understanding of the current and anticipated effects of climate-related risks and opportunities on the issuer's business model and value chain.		Chapter 4.1.2 Strategy
Strategy and decision-making An issuer shall disclose information that enables an understanding of the effects of climate-related risks and opportunities on its strategy and decision-making.		Chapter 4.1.2 Strategy

Subject Areas, Aspects, General Disclosures and KPIs	Index
Part D: Climate-related Disclosures	
(III) Risk Management	
The processes and related policies the issuer uses to identify, assess, prioritise and monitor climate-related risks.	Chapter 1.3.1 Internal Control and Risk Management Structure Chapter 4.1.3 Risk Management
The processes the issuer uses to identify, assess, prioritise and monitor climate-related opportunities.	Chapter 1.3.1 Internal Control and Risk Management Structure Chapter 4.1.3 Risk Management
The extent to which, and how, the processes for identifying, assessing, prioritising and monitoring climate-related risks and opportunities are integrated into and inform the issuer's overall risk management process.	Chapter 1.3.1 Internal Control and Risk Management Structure Chapter 4.1.3 Risk Management
(IV) Metrics and Targets	
Greenhouse gas emissions An issuer shall disclose its absolute gross greenhouse gas emissions generated during the Reporting Period, expressed as metric tons of CO_2 equivalent.	Chapter 4.1.4 Metrics and Target Tracking
Climate-related targets An issuer shall disclose (a) the qualitative and quantitative climate-related targets the issuer has set to monitor progress towards achieving its strategic goals; and (b) any targets the issuer is required to meet by law or regulation, including any greenhouse gas emissions targets.	Chapter 4.1.4 Metrics and Target Tracking

Appendix II: TCFD Index

TCFD Disclosure Recommendations	Index
Governance	
a) Describe the Board's oversight of climate-related risks and opportunities. b) Describe management's role in assessing and managing climate related risks and opportunities.	The supervision of climate-related risks and opportunities is led by the Board, with the cooperation of the Risk Management Committee and the ESG Working Group. For more details, please refer to Chapter 4.1.1
Strategy	
a) Describe the climate-related risks and opportunities the organization has identified over the short, medium and long term. b) Describe the impact of climate-related risks and opportunities on the organization's businesses, strategy and financial planning. c) Describe the resilience of the organization's strategy, taking into consideration different climate-related scenarios, including a 2°C or lower scenario.	The Company has developed a climate-related risk identification list with reference to IPCC climate change scenarios and taking into account business characteristics and industry characteristics, which includes an analysis of the costs and potential impacts of the identified risks on the Company's business operations. In response to the identified extreme weather conditions, the Company has developed a series of countermeasures. For more details, please refer to Chapter 4.1.2
Risk management	
a) Describe the process of identifying and assessing climate-related risks in the organization. b) Describe the process of managing climate-related risks in the organization. c) Describe how the processes of identifying, assessing, and managing climate-related risks are integrated into the organization's overall risk management.	The Company has established a comprehensive internal control and risk management framework that incorporates climate-related risk management responsibilities. The Risk Management Committee is responsible for identifying and evaluating climate-related risks and assessing the effectiveness of countermeasures, while the ESG Working Group is responsible for implementing measures to address climate-related risks, continuously monitoring progress towards established targets and the execution of measures, and providing timely feedback to the Risk Management Committee. For more details, please refer to Chapter 4.1.3, 1.3.1
Metrics and targets	
a) Disclose the metrics used by the organization to assess climate-related risks and opportunities in line with its strategy and risk management process. b) Disclose direct emissions (Scope 1), indirect emissions (Scope 2), other indirect emissions (Scope 3) (if required) of greenhouse gas (GHG) and associated risks. c) Describe the targets used by the organization to manage climate related risks and opportunities and performance against targets.	The Company set specific targets for energy consumption and GHG emissions in 2021: to reduce the intensity of comprehensive energy consumption and GHG emissions (Scopes 1 and 2) by 40% in 2025 compared to 2021. In 2024, the Company's comprehensive energy consumption intensity was 0.52 MWh/RMB10,000 revenue, a decrease of 84% compared to 2021; and the GHG emission intensity (Scopes 1 and 2) was 0.25 tCO_2e/RMB10,000 revenue, a decrease of 86% compared to 2021. For more details, please refer to Chapter 4.1.4